Erik De Clercq

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3825351/publications.pdf

Version: 2024-02-01

745	45,431	2203	3476
papers	citations	99 h-index	182 g-index

827	827	827	31410
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods, 1988, 20, 309-321.	1.0	1,644
2	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, 2020, 19, 149-150.	21.5	1,370
3	Approved Antiviral Drugs over the Past 50 Years. Clinical Microbiology Reviews, 2016, 29, 695-747.	5.7	1,049
4	CXCR4-activated astrocyte glutamate release via TNFÎ±: amplification by microglia triggers neurotoxicity. Nature Neuroscience, 2001, 4, 702-710.	7.1	996
5	Antiviral drugs in current clinical use. Journal of Clinical Virology, 2004, 30, 115-133.	1.6	860
6	Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 1990, 343, 470-474.	13.7	794
7	A novel selective broad-spectrum anti-DNA virus agent. Nature, 1986, 323, 464-467.	13.7	782
8	Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. Journal of Medicinal Chemistry, 1995, 38, 2491-2517.	2.9	711
9	Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature Reviews Drug Discovery, 2005, 4, 928-940.	21.5	587
10	Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery, 2006, 5, 1015-1025.	21.5	586
11	Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology, 2006, 147, 1-11.	2.7	572
12	Strategies in the design of antiviral drugs. Nature Reviews Drug Discovery, 2002, 1, 13-25.	21.5	566
13	Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4. Journal of Experimental Medicine, 1997, 186, 1383-1388.	4.2	559
14	Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Research, 1987, 8, 261-272.	1.9	518
15	Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. International Journal of Antimicrobial Agents, 2009, 33, 307-320.	1.1	510
16	Update on Human Herpesvirus 6 Biology, Clinical Features, and Therapy. Clinical Microbiology Reviews, 2005, 18, 217-245.	5.7	466
17	The bicyclam AMD3100 story. Nature Reviews Drug Discovery, 2003, 2, 581-587.	21.5	422
18	A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry, 1989, 32, 2507-2509.	2.9	396

#	Article	IF	Citations
19	The design of drugs for HIV and HCV. Nature Reviews Drug Discovery, 2007, 6, 1001-1018.	21.5	377
20	The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5â€“10 April 1998.1. Antiviral Research, 1998, 38, 153-179.	1.9	350
21	Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?. Journal of Medicinal Chemistry, 2010, 53, 521-538.	2.9	343
22	Both 2â€²,3â€²-dideoxythymidine and its 2â€²,3â€²-unsaturated derivative (2â€²,3â€²-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochemical and Biophysical Research Communications, 1987, 142, 128-134.	1.0	329
23	Antivirals and antiviral strategies. Nature Reviews Microbiology, 2004, 2, 704-720.	13.6	327
24	Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Research, 1987, 7, 361-367.	1.9	326
25	Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections. Clinical Microbiology Reviews, 2003, 16, 569-596.	5.7	324
26	Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nature Protocols, 2008, 3, 427-434.	5.5	324
27	Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Medicinal Research Reviews, 2000, 20, 323-349.	5.0	321
28	Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Letters, 1979, 8, 9-22.	3.2	278
29	The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replicationin vitro. Hepatology, 2006, 43, 761-770.	3.6	272
30	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. Journal of Medicinal Chemistry, 2016, 59, 2849-2878.	2.9	260
31	Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). Journal of Medicinal Chemistry, 1986, 29, 1561-1569.	2.9	250
32	The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil). Biochemical Pharmacology, 2009, 77, 1655-1664.	2.0	250
33	Cidofovir in the treatment of poxvirus infections. Antiviral Research, 2002, 55, 1-13.	1.9	243
34	Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. , 1998, 54, 219-225.		240
35	Antiviral drugs: current state of the art. Journal of Clinical Virology, 2001, 22, 73-89.	1.6	239
36	New Approaches toward Anti-HIV Chemotherapyâ€¡. Journal of Medicinal Chemistry, 2005, 48, 1297-1313.	2.9	238

#	Article	IF	Citations
37	HIV resistance to reverse transcriptase inhibitors. Biochemical Pharmacology, 1994, 47, 155-169.	2.0	234
38	Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis. Antiviral Therapy, 2004, 9, 57-65.	0.6	228
39	Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4. Antiviral Research, 1997, 35, 147-156.	1.9	223
40	Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future. Chemistry and Biodiversity, 2004, 1, 44-64.	1.0	219
41	New anti-HIV agents and targets. Medicinal Research Reviews, 2002, 22, 531-565.	5.0	215
42	Synthesis and antiviral activity of imidazo[1,2-a]pyridines. European Journal of Medicinal Chemistry, 1999, 34, 271-274.	2.6	213
43	New developments in anti-HIV chemotherapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1587, 258-275.	1.8	212
44	Clinical features and treatment of adenovirus infections. Reviews in Medical Virology, 2008, 18, 357-374.	3.9	210
45	S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochemical Pharmacology, 1987, 36, 2567-2575.	2.0	201
46	Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. Journal of Virological Methods, 1987, 16, 171-185.	1.0	192
47	Current drug research on PEGylation with small molecular agents. Progress in Polymer Science, 2013, 38, 421-444.	11.8	190
48	Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1Î±. FEBS Letters, 1998, 432, 73-76.	1.3	187
49	Highly Potent and Selective Inhibition of Varicella-Zoster Virus by Bicyclic Furopyrimidine Nucleosides Bearing an Aryl Side Chain. Journal of Medicinal Chemistry, 2000, 43, 4993-4997.	2.9	187
50	Synthesis of Imidazo[1,2-a]pyridines as Antiviral Agents. Journal of Medicinal Chemistry, 1998, 41, 5108-5112.	2.9	186
51	Potent and Selective Inhibition of Varicella-Zoster Virus (VZV) by Nucleoside Analogues with an Unusual Bicyclic Base. Journal of Medicinal Chemistry, 1999, 42, 4479-4484.	2.9	181
52	HIV-1-specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Medicinal Research Reviews, 1993, 13, 229-258.	5.0	180
53	Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature, 2006, 439, 745-748.	13.7	180
54	A Novel Approach for the Virtual Screening and Rational Design of Anticancer Compounds. Journal of Medicinal Chemistry, 2000, 43, 1975-1985.	2.9	176

#	Article	IF	Citations
55	Expression of human fibroblast interferon gene in Escherichia coli. Nature, 1980, 287, 193-197.	13.7	170
56	HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase. Virology, 1993, 192, 246-253.	1.1	169
57	New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections. Chemistry - an Asian Journal, 2019, 14, 3962-3968.	1.7	166
58	HIVâ€1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design. Medicinal Research Reviews, 2013, 33, E1-72.	5.0	161
59	The history of antiretrovirals: key discoveries over the past 25 years. Reviews in Medical Virology, 2009, 19, 287-299.	3.9	159
60	Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Reviews in Medical Virology, 2001, 11, 381-395.	3.9	157
61	The HIV-1 Reverse Transcription (RT) Process as Target for RT Inhibitors. , 2000, 20, 129-154.		156
62	Antiviral drug discovery and development: Where chemistry meets with biomedicine. Antiviral Research, 2005, 67, 56-75.	1.9	153
63	Antiviral Agents: Characteristic Activity Spectrum Depending on the Molecular Target With Which They Interact. Advances in Virus Research, 1993, 42, 1-55.	0.9	152
64	C-Nucleosides To Be Revisited. Journal of Medicinal Chemistry, 2016, 59, 2301-2311.	2.9	148
65	Differential signalling of the chemokine receptor CXCR4 by stromal cell-derived factor 1 and the HIV glycoprotein in rat neurons and astrocytes. European Journal of Neuroscience, 2000, 12, 117-125.	1.2	146
66	A 40-Year Journey in Search of Selective Antiviral Chemotherapy*. Annual Review of Pharmacology and Toxicology, 2011, 51, 1-24.	4.2	145
67	Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2. Journal of Medicinal Chemistry, 1996, 39, 3307-3318.	2.9	144
68	The acyclic nucleoside phosphonates from inception to clinical use: Historical perspective. Antiviral Research, 2007, 75, 1-13.	1.9	143
69	Antiretroviral drugs. Current Opinion in Pharmacology, 2010, 10, 507-515.	1.7	143
70	Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Review of Anti-Infective Therapy, 2006, 4, 291-302.	2.0	142
71	Nucleoside Inhibitors of Zika Virus. Journal of Infectious Diseases, 2016, 214, 707-711.	1.9	142
72	Emerging anti-HIV drugs. Expert Opinion on Emerging Drugs, 2005, 10, 241-274.	1.0	137

#	Article	IF	Citations
73	Potent and selective anti-HTLV-IIILAV activity of 2â€²,3â€²-dideoxycytidinene, the 2â€²,3â€²-unsaturated derivative of 2â€²,3â€²-dideoxycytidine. Biochemical and Biophysical Research Communications, 1986, 140, 735-742.	1.0	135
74	Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice. Antimicrobial Agents and Chemotherapy, 1998, 42, 1568-1573.	1.4	135
75	Recent highlights in the development of new antiviral drugs. Current Opinion in Microbiology, 2005, 8, 552-560.	2.3	135
76	Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Research, 2017, 142, 83-122.	1.9	135
77	Betulinic Acid Derivatives:Â A New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1 Entry. Journal of Medicinal Chemistry, 1996, 39, 1069-1083.	2.9	130
78	6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with Antiviral Activity. Journal of Medicinal Chemistry, 2002, 45, 1918-1929.	2.9	129
79	Highlights in the Discovery of Antiviral Drugs: A Personal Retrospective. Journal of Medicinal Chemistry, 2010, 53, 1438-1450.	2.9	129
80	Betulinic Acid Derivatives:Â A New Class of Human Immunodeficiency Virus Type 1 Specific Inhibitors with a New Mode of Action. Journal of Medicinal Chemistry, 1996, 39, 1056-1068.	2.9	125
81	Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. , 1998, 32, 350-361.		123
82	Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Letters, 2007, 48, 8472-8474.	0.7	123
83	Synthesis and Antiviral Activity Evaluation of Some Aminoadamantane Derivatives. Journal of Medicinal Chemistry, 1994, 37, 2896-2902.	2.9	119
84	Biological Evaluation of Proanthocyanidin Dimers and Related Polyphenols. Journal of Natural Products, 1999, 62, 954-958.	1.5	119
85	Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochemical Pharmacology, 2016, 119, 1-7.	2.0	119
86	Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides. Journal of Medicinal Chemistry, 1988, 31, 2040-2048.	2.9	117
87	Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance development. , 1996, 16, 125-157.		116
88	The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochemical Pharmacology, 2011, 82, 99-109.	2.0	116
89	Strategies for the Design of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Lessons from the Development of Seven Representative Paradigms. Journal of Medicinal Chemistry, 2012, 55, 3595-3613.	2.9	115
90	Antivirals: Past, present and future. Biochemical Pharmacology, 2013, 85, 727-744.	2.0	115

#	Article	IF	Citations
91	Deoxythreosyl Phosphonate Nucleosides as Selective Anti-HIV Agents. Journal of the American Chemical Society, 2005, 127, 5056-5065.	6.6	114
92	Synthesis and antiviral activity of water-soluble esters of acyclovir	2.9	113
93	Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antiviral Chemistry and Chemotherapy, 2018, 26, 204020661876129.	0.3	113
94	Conformational and Quantitative Structureâ^'Activity Relationship Study of Cytotoxic 2-Arylidenebenzocycloalkanones. Journal of Medicinal Chemistry, 1999, 42, 1358-1366.	2.9	110
95	Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochemical Pharmacology, 1984, 33, 2159-2169.	2.0	109
96	Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. Journal of Medical Virology, 1993, 41, 242-246.	2.5	108
97	Overview of Recent Strategic Advances in Medicinal Chemistry. Journal of Medicinal Chemistry, 2019, 62, 9375-9414.	2.9	108
98	Synthesis and Structureâ^'Activity Relationships of Phenylenebis(methylene)- Linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4. Journal of Medicinal Chemistry, 1999, 42, 3971-3981.	2.9	107
99	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. Journal of Medicinal Chemistry, 2016, 59, 7991-8007.	2.9	107
100	Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV). International Journal of Cancer, 1986, 37, 451-457.	2.3	106
101	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent. Antimicrobial Agents and Chemotherapy, 2008, 52, 1302-1317.	1.4	106
102	Antiviral Activity Spectrum and Target of Action of Different Classes of Nucleoside Analogues. Nucleosides & Nucleotides, 1994, 13, 1271-1295.	0.5	104
103	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: Structural modulations of diaryltriazines with potent anti-HIV activity. European Journal of Medicinal Chemistry, 2008, 43, 1230-1236.	2.6	102
104	Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobilâ„¢) and potential of other CXCR4 antagonists as stem cell mobilizers. , 2010, 128, 509-518.		101
105	Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides. Journal of Medicinal Chemistry, 1983, 26, 661-666.	2.9	100
106	MozobilÂ® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antiviral Chemistry and Chemotherapy, 2019, 27, 204020661982938.	0.3	100
107	5-substituted 2â€²-deoxyuridines: Correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. Biochemical Pharmacology, 1982, 31, 3673-3682.	2.0	97
108	5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidinesAcyclic Nucleoside Phosphonate Analogues with Antiviral Activity. Journal of Medicinal Chemistry, 2003, 46, 5064-5073.	2.9	97

#	Article	IF	Citations
109	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. European Journal of Medicinal Chemistry, 2008, 43, 2800-2806.	2.6	97
110	Managing Resistance to Anti-HIV Drugs. Drugs, 1999, 57, 337-361.	4.9	95
111	New acquisitions in the development of anti-HIV agents. Antiviral Research, 1989, 12, 1-19.	1.9	94
112	HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. International Journal of Biochemistry and Cell Biology, 2004, 36, 1800-1822.	1.2	94
113	Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. , 1984, 26, 1-44.		93
114	Anti-Hiv-1 Activity of 2',3'-Dideoxinucleoside Analogues : Structure-Activity Relationship. Nucleosides, Nucleotides and Nucleic Acids, 1989, 8, 659-671.	0.4	92
115	Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Current Medicinal Chemistry, 2009, 16, 3903-3917.	1.2	92
116	Diverging binding capacities of natural LD78Î² isoforms of macrophage inflammatory protein-1Î± to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. European Journal of Immunology, 2001, 31, 2170-2178.	1.6	91
117	Design and synthesis of bioactive adamantane spiro heterocycles. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4358-4362.	1.0	90
118	Clinical significance of chemokine receptor antagonists. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 11-30.	1.5	90
119	Aurintricarboxylic acid and evans blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochemical and Biophysical Research Communications, 1986, 136, 64-71.	1.0	89
120	Novel compounds in preclinical/early clinical development for the treatment of HIV infections. Reviews in Medical Virology, 2000, 10, 255-277.	3.9	89
121	Evolution of anti-HIV drug candidates. Part 1: From Î±-Anilinophenylacetamide (Î±-APA) to imidoyl thiourea (ITU). Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2225-2228.	1.0	87
122	Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chemical Society Reviews, 2021, 50, 4514-4540.	18.7	84
123	Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. Aids, 1998, 12, 1129-1138.	1.0	83
124	Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochemical Pharmacology, 2014, 89, 441-452.	2.0	83
125	5â€²-Nor Carbocyclic 5â€²-Deoxy-5â€²-(Isobutylthio)Adenosine and a 2â€²,3â€²-Dideoxy-2â€²,3â€²-Didehydro Derivative. Antiviral Chemistry and Chemotherapy, 2001, 12, 119-124.	0.3	82
126	Suramin in the treatment of AIDS: Mechanism of action. Antiviral Research, 1987, 7, 1-10.	1.9	81

#	Article	IF	Citations
127	The Cyclohexene Ring System as a Furanose Mimic:â€‰ Synthesis and Antiviral Activity of Both Enantiomers of Cyclohexenylguanine. Journal of Medicinal Chemistry, 2000, 43, 736-745.	2.9	81
128	The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication. Molecular Pharmacology, 2006, 69, 1461-1467.	1.0	80
129	Nucleoside Inhibitors of Tick-Borne Encephalitis Virus. Antimicrobial Agents and Chemotherapy, 2015, 59, 5483-5493.	1.4	80
130	Synthesis and antiviral activity of 3-substituted imidazo[1,2-a]pyridines.. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1937-1940.	1.0	79
131	Antiviral Activity of Triazine Analogues of 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds. Journal of Medicinal Chemistry, 2007, 50, 1069-1077.	2.9	79
132	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry, 2017, 60, 4424-4443.	2.9	79
133	Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. Acta Pharmaceutica Sinica B, 2020, 10, 961-978.	5.7	79
134	Potential Clinical Applications of the CXCR4 Antagonist Bicyclam AMD3100. Mini-Reviews in Medicinal Chemistry, 2005, 5, 805-824.	1.1	77
135	Another ten stories in antiviral drug discovery (part C): â€œOldâ€•and â€œnewâ€•antivirals, strategies, and perspectives. Medicinal Research Reviews, 2009, 29, 611-645.	5.0	77
136	Activity of the Anti-Orthopoxvirus Compound ST-246 against Vaccinia, Cowpox and Camelpox Viruses in Cell Monolayers and Organotypic Raft Cultures. Antiviral Therapy, 2007, 12, 1205-1216.	0.6	77
137	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. European Journal of Medicinal Chemistry, 2015, 92, 754-765.	2.6	76
138	Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Review of Anti-Infective Therapy, 2003, 1, 21-43.	2.0	75
139	Acyclic Nucleotide Analogs Derived from 8-Azapurines:Â Synthesis and Antiviral Activity. Journal of Medicinal Chemistry, 1996, 39, 4073-4088.	2.9	74
140	Nuclear Localization of Human Immunodeficiency Virus Type 1 Integrase Expressed as a Fusion Protein with Green Fluorescent Protein. Virology, 1999, 258, 327-332.	1.1	74
141	Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). , 2000, 60, 205-209.		74
142	Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends in Pharmacological Sciences, 2002, 23, 456-458.	4.0	74
143	Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Reviews in Medical Virology, 2004, 14, 289-300.	3.9	74
144	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells. European Journal of Medicinal Chemistry, 2016, 121, 58-70.	2.6	73

#	Article	IF	Citations
145	Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. Antiviral Research, 2017, 142, 63-67.	1.9	73
146	Synthesis, Characterization and in Vitro Study of the Cytostatic and Antiviral Activity of New Polymeric Silver(I) Complexes with Ribbon Structures Derived from the Conjugated Heterocyclic Thioamide 2-Mercapto-3,4,5,6-tetra- hydropyrimidine. European Journal of Inorganic Chemistry, 2004, 2004, 1420-1426.	1.0	71
147	The discovery of antiviral agents: Ten different compounds, ten different stories. Medicinal Research Reviews, 2008, 28, 929-953.	5.0	71
148	The Thiazolobenzimidazole TBZE-029 Inhibits Enterovirus Replication by Targeting a Short Region Immediately Downstream from Motif C in the Nonstructural Protein 2C. Journal of Virology, 2008, 82, 4720-4730.	1.5	71
149	Selective Anti-Herpesvirus Agents. Antiviral Chemistry and Chemotherapy, 2013, 23, 93-101.	0.3	71
150	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: Design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorganic and Medicinal Chemistry, 2014, 22, 2052-2059.	1.4	71
151	Identification of Dihydrofuro[3,4-d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. Journal of Medicinal Chemistry, 2019, 62, 1484-1501.	2.9	70
152	Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochemical Pharmacology, 2004, 67, 325-336.	2.0	69
153	Anti-influenza virus agents: Synthesis and mode of action. Medicinal Research Reviews, 2008, 28, 1-38.	5.0	69
154	Ebola virus (EBOV) infection: Therapeutic strategies. Biochemical Pharmacology, 2015, 93, 1-10.	2.0	69
155	Evaluation of Hexadecyloxypropyl-9- R -[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 3505-3509.	1.4	68
156	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. European Journal of Medicinal Chemistry, 2018, 151, 339-350.	2.6	68
157	The 2â€²,3â€²-dideoxyriboside of 2,6-diaminopurine selectively inhibits human immunodeficiency virus (HIV) replication invitro. Biochemical and Biophysical Research Communications, 1987, 145, 269-276.	1.0	67
158	Current Pharmacological Approaches to the Therapy of Varicella Zoster Virus Infections. Drugs, 1999, 57, 187-206.	4.9	67
159	Synthesis and Biological Evaluation of Acyclic 3-[(2-Hydroxyethoxy)methyl] Analogues of Antiviral Furo- and Pyrrolo[2,3-d]pyrimidine Nucleosides1. Journal of Medicinal Chemistry, 2005, 48, 4690-4696.	2.9	67
160	Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Reviews in Medical Virology, 2008, 18, 19-34.	3.9	67
161	Alkyl esters of 3-adenin-9-yl-2-hydroxypropanoic acid: a new class of broad-spectrum antiviral agents. Journal of Medicinal Chemistry, 1985, 28, 282-287.	2.9	66
162	7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase. FEBS Letters, 1998, 438, 91-95.	1.3	66

#	Article	IF	Citations
163	ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 331-341.	0.4	66
164	Benzylidene/2-chlorobenzylidene hydrazides: Synthesis, antimicrobial activity, QSAR studies and antiviral evaluation. European Journal of Medicinal Chemistry, 2010, 45, 2806-2816.	2.6	66
165	Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. Antiviral Research, 2016, 133, 119-129.	1.9	66
166	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. Journal of Medicinal Chemistry, 2019, 62, 2083-2098.	2.9	66
167	Antiviral potency of adenosine analogues: Correlation with inhibition of S-adenosylhomocysteine hydrolase. Biochemical and Biophysical Research Communications, 1985, 129, 306-311.	1.0	65
168	Susceptibilities of Several Clinical Varicella-Zoster Virus (VZV) Isolates and Drug-Resistant VZV Strains to Bicyclic Furano Pyrimidine Nucleosides. Antimicrobial Agents and Chemotherapy, 2005, 49, 1081-1086.	1.4	65
169	Potential Use of Antiviral Agents in Polio Eradication. Emerging Infectious Diseases, 2008, 14, 545-551.	2.0	65
170	Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2). Clinical and Translational Immunology, 2020, 9, e1182.	1.7	65
171	Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Reviews in Medical Virology, 1995, 5, 149-164.	3.9	64
172	Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia. Antimicrobial Agents and Chemotherapy, 2004, 48, 2267-2273.	1.4	64
173	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 5775-5781.	1.4	64
174	The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS). Advances in Pharmacology, 2013, 67, 317-358.	1.2	63
175	Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. Journal of Medical Virology, 1992, 37, 67-71.	2.5	62
176	Fifty Years in Search of Selective Antiviral Drugs. Journal of Medicinal Chemistry, 2019, 62, 7322-7339.	2.9	62
177	Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture:â€‰ Structural Determinants for in Vitro Activity and QSAR. Journal of Medicinal Chemistry, 1999, 42, 4122-4128.	2.9	61
178	Discovery of a New Family of Inhibitors of Human Cytomegalovirus (HCMV) Based upon Lipophilic Alkyl Furano Pyrimidine Dideoxy Nucleosides:â€‰ Action via a Novel Non-Nucleosidic Mechanism. Journal of Medicinal Chemistry, 2004, 47, 1847-1851.	2.9	61
179	HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiology and Molecular Biology Reviews, 2016, 80, 679-731.	2.9	61
180	What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?. , 1996, 6, 97-117.		60

#	Article	IF	Citations
181	Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1053-1056.	1.0	60
182	Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues. Medicinal Research Reviews, 2003, 23, 253-274.	5.0	60
183	AMD3100/CXCR4 Inhibitor. Frontiers in Immunology, 2015, 6, 276.	2.2	60
184	Computational Strategies in Discovering Novel Non-nucleoside Inhibitors of HIV-1 RT. Journal of Medicinal Chemistry, 2005, 48, 3433-3437.	2.9	58
185	1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation. Bioorganic and Medicinal Chemistry, 2009, 17, 6374-6379.	1.4	58
186	Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies. Medicinal Chemistry Research, 2012, 21, 1451-1470.	1.1	58
187	Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1183-1186.	1.0	57
188	Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends in Pharmacological Sciences, 2007, 28, 280-285.	4.0	57
189	Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds. Bioorganic and Medicinal Chemistry, 2007, 15, 6632-6641.	1.4	57
190	Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 813-829.	1.5	57
191	Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses, 2010, 2, 1279-1305.	1.5	56
192	Conversion of 2â€²,3â€²-dideoxyadenosine (ddA) and 2â€²,3â€²-didehydro-2â€²,3â€²-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Letters, 1997, 410, 324-328.	1.3	55
193	Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice. Antimicrobial Agents and Chemotherapy, 2003, 47, 777-782.	1.4	55
194	The Interferon Inducer Ampligen [Poly(I)-Poly(C 12 U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis. Antimicrobial Agents and Chemotherapy, 2004, 48, 267-274.	1.4	55
195	Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. Journal of Clinical Virology, 2006, 37, S69-S75.	1.6	55
196	Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antiviral Research, 1996, 31, 159-164.	1.9	54
197	Synthesis and Studies of New 2â€(Coumarinâ€4â€yloxy)â€4,6â€(substituted)â€sâ€Triazine Derivatives as Potential Antiâ€HIV Agents. Archiv Der Pharmazie, 2009, 342, 281-290.	2.1	54
198	Antiviral drug discovery: Ten more compounds, and ten more stories (part B). Medicinal Research Reviews, 2009, 29, 571-610.	5.0	54

#	Article	IF	Citations
199	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of nicotinic acid benzylidene hydrazide derivatives. Medicinal Chemistry Research, 2012, 21, 1557-1576.	1.1	54
200	Towards an Effective Chemotherapy of Virus Infections: Therapeutic Potential of Cidofovir [(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine, HPMPC] for the Treatment of DNA Virus Infections. Collection of Czechoslovak Chemical Communications, 1998, 63, 480-506.	1.0	53
201	In search of a selective therapy of viral infections. Antiviral Research, 2010, 85, 19-24.	1.9	53
202	A Cuttingâ€Edge View on the Current State of Antiviral Drug Development. Medicinal Research Reviews, 2013, 33, 1249-1277.	5.0	53
203	Chimeric Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Reverse Transcriptases: Role of the Subunits in Resistance/Sensitivity to Non-Nucleoside Reverse Transcriptase Inhibitors. Molecular Pharmacology, 2002, 61, 400-406.	1.0	52
204	John Montgomery's Legacy: Carbocyclic Adenosine Analogues as Sah Hydrolase Inhibitors with Broad-Spectrum Antiviral Activity. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1395-1415.	0.4	52
205	Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1014-1023.	1.1	52
206	Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (pmea)in vivo increases when it is less frequently administered. International Journal of Cancer, 1990, 46, 337-340.	2.3	51
207	Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antiviral Research, 1997, 36, 35-42.	1.9	51
208	Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: Impact on the search for vaginal microbicides. , 2000, 61, 107-110.		51
209	Specific Recognition of the Bicyclic Pyrimidine Nucleoside Analogs, a New Class of Highly Potent and Selective Inhibitors of Varicella-Zoster Virus (VZV), by the VZV-Encoded Thymidine Kinase. Molecular Pharmacology, 2002, 61, 249-254.	1.0	51
210	Highlights in Antiviral Drug Research: Antivirals at the Horizon. Medicinal Research Reviews, 2013, 33, 1215-1248.	5.0	51
211	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 85, 293-303.	2.6	51
212	Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazolineâ€“triazine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 100-108.	2.5	51
213	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. Antiviral Therapy, 2003, 8, 1-8.	0.6	51
214	Ester Prodrugs of Cyclic 1-(S)- [3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine:â€‰ Synthesis and Antiviral Activity. Journal of Medicinal Chemistry, 2007, 50, 5765-5772.	2.9	50
215	Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 4837-4848.	2.9	50
216	Synthesis and antiviral activity of novel [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and [1,2,4]triazolo[3,4-b][1,3,4] thiadiazepines. Arkivoc, 2006, 2006, 137-151.	0.3	50

#	Article	IF	Citations
217	In Vitro and In Vivo Inhibition of Murine Gamma Herpesvirus 68 Replication by Selected Antiviral Agents. Antimicrobial Agents and Chemotherapy, 1998, 42, 170-172.	1.4	49
218	Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study. Aging, 2021, 13, 27-60.	1.4	49
219	New Neplanocin Analogues. 7. Synthesis and Antiviral Activity of 2-Halo Derivatives of Neplanocin A1. Journal of Medicinal Chemistry, 1996, 39, 3847-3852.	2.9	48
220	Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharmaceutical Research, 1997, 14, 492-496.	1.7	48
221	New inhibitors of human cytomegalovirus (HCMV) on the horizon. Journal of Antimicrobial Chemotherapy, 2003, 51, 1079-1083.	1.3	48
222	Recent Advances in the Search for Selective Antiviral Agents. Advances in Drug Research, 1988, 17, 1-59.	0.8	48
223	New synthesis and anti-HIV and antiviral properties of 3-arylsulfonyl derivatives of 4-ydroxycoumarin and 4-hydroxyquinolone. Pharmaceutical Chemistry Journal, 2008, 42, 265-270.	0.3	47
224	Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. Antiviral Research, 2010, 85, 34-38.	1.9	47
225	Highâ€level expression of active HIVâ€1 integrase from a synthetic gene in human cells. FASEB Journal, 2000, 14, 1389-1399.	0.2	46
226	Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir. A Structureâ^'Antiviral Activity Study. Journal of Medicinal Chemistry, 2001, 44, 4284-4287.	2.9	46
227	(E)-5-(2-bromovinyl)-2?-deoxyuridine (BVDU). Medicinal Research Reviews, 2005, 25, 1-20.	5.0	46
228	Synthesis of mono-, bis-spiro- and dispiro-Î²-lactams and evaluation of their antimalarial activities. Tetrahedron, 2011, 67, 8699-8704.	1.0	46
229	Role of the Human Herpesvirus 6 U69-Encoded Kinase in the Phosphorylation of Ganciclovir. Molecular Pharmacology, 2002, 62, 714-721.	1.0	45
230	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 4648-4653.	2.6	45
231	3â€²â€(1,2,3â€Triazolâ€1â€yl)â€2â€²,3â€²â€dideoxythymidine and 3â€²â€(1,2,3â€triazolâ€1â€yl)â€2â€²,3â€²â€dideoxyuridine. Journal of Medicinal Chemistry, 1989, 26, 1635-1642.	1.4	45
232	Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (Î±-cya Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 1778-1786.	2.9	44
233	Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity. Bioorganic and Medicinal Chemistry, 2009, 17, 1534-1541.	1.4	44
234	Milestones in the discovery of antiviral agents: nucleosides and nucleotides. Acta Pharmaceutica Sinica B, 2012, 2, 535-548.	5.7	44

#	Article	IF	Citations
235	Selective antiherpes agents. Trends in Pharmacological Sciences, 1982, 3, 492-495.	4.0	43
236	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 7429-7435.	1.4	43
237	Structural Modifications of DAPY Analogues with Potent Antiâ€HIVâ€1 Activity. ChemMedChem, 2009, 4, 219-224.	1.6	43
238	Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Antiviral Research, 1998, 40, 53-56.	1.9	42
239	Design, synthesis, and structureâ€“activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents. Bioorganic and Medicinal Chemistry, 2009, 17, 5962-5967.	1.4	42
240	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. European Journal of Medicinal Chemistry, 2018, 145, 726-734.	2.6	42
241	DNA Polymerase Mutations in Drug-Resistant Herpes Simplex Virus Mutants Determine In Vivo Neurovirulence and Drug-Enzyme Interactions. Antiviral Therapy, 2007, 12, 719-732.	0.6	42
242	New Neplanocin Analogues. 6. Synthesis and Potent Antiviral Activity of 6â€˜-Homoneplanocin A. Journal of Medicinal Chemistry, 1996, 39, 2392-2399.	2.9	41
243	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. European Journal of Medicinal Chemistry, 2015, 93, 330-337.	2.6	41
244	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. Journal of Medicinal Chemistry, 2020, 63, 4790-4810.	2.9	41
245	Potent interferon inducer derived from poly(7-deazainosinic acid). Biochemistry, 1974, 13, 4400-4408.	1.2	40
246	Are the 2-Isomers of the Drug Rimantadine Active Anti-Influenza a Agents?. Antiviral Chemistry and Chemotherapy, 2003, 14, 153-164.	0.3	40
247	Emerging antiviral drugs. Expert Opinion on Emerging Drugs, 2008, 13, 393-416.	1.0	40
248	Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides. Medicinal Chemistry Research, 2012, 21, 1935-1952.	1.1	40
249	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2014, 22, 1863-1872.	1.4	40
250	Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3â€² untranslated region of flaviviruses with no known vector. Journal of General Virology, 2002, 83, 1875-1885.	1.3	40
251	5'-O-Phosphonomethyl-2',3'-dideoxynucleosides: synthesis and anti-HIV activity. Journal of Medicinal Chemistry, 1990, 33, 2481-2487.	2.9	39
252	Synthesis and antiviral activity of phosphonate derivatives of enantiomeric dihydro-2H-pyranyl nucleosides. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1115-1118.	1.0	39

#	Article	IF	Citations
253	Phosphoramidate derivatives of 2â€²,3â€²-didehydro-2â€²,3â€²-dideoxyadenosine [d4A] have markedly improved anti-HIV potency and selectivity. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2359-2362.	1.0	39
254	Anti-enterovirus activity and structureâ€“activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochemical and Biophysical Research Communications, 2007, 353, 628-632.	1.0	39
255	Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Organic and Biomolecular Chemistry, 2019, 17, 3202-3217.	1.5	39
256	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharmaceutica Sinica B, 2020, 10, 878-894.	5.7	39
257	Charge modification of plasma and milk proteins results in antiviral active compounds. Journal of Peptide Science, 1999, 5, 563-576.	0.8	38
258	Design, Synthesis, and SAR of Naphthylâ€Substituted Diarylpyrimidines as Nonâ€Nucleoside Inhibitors of HIVâ€1 Reverse Transcriptase. ChemMedChem, 2009, 4, 1537-1545.	1.6	38
259	The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Medicinal Research Reviews, 2011, 31, 118-160.	5.0	38
260	Stabilisation of interferons by defensive reversible denaturation. Nature, 1974, 249, 460-461.	13.7	37
261	Studies into the synthesis of derivatives of 4-amino-2,3-dihydroisothiazole 1,1-dioxides and 4-amino-1,2-oxathiole 2,2-dioxides: The search for linked Ï€-system containing analogues as potential inhibitors of HIV-1 reverse transcriptase. Tetrahedron, 1997, 53, 17795-17814.	1.0	37
262	Halogenated sesquiterpenes from the red alga Laurencia obtusa. Tetrahedron, 2002, 58, 6749-6755.	1.0	37
263	In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Research, 2007, 75, 52-57.	1.9	37
264	Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. Biochemical Pharmacology, 2012, 84, 241-248.	2.0	37
265	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. Journal of Medicinal Chemistry, 2020, 63, 1298-1312.	2.9	37
266	Antiviral, antimetabolic and antineoplastic activities of 2â€²-or 3â€²-amino or -azido-substituted deoxyribonucleosides. Biochemical Pharmacology, 1980, 29, 1849-1851.	2.0	36
267	3â€²-C-Trifluoromethyl Ribonucleosides. Nucleosides & Nucleotides, 1995, 14, 185-194.	0.5	36
268	The Acyclic Nucleoside Phosphonates (ANPs): AntonÃn HolÃ½'s Legacy. Medicinal Research Reviews, 2013, 33, 1278-1303.	5.0	36
269	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. European Journal of Medicinal Chemistry, 2014, 87, 52-62.	2.6	36
270	Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochemical Pharmacology, 2018, 153, 2-11.	2.0	36

#	Article	IF	Citations
271	Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: Report of a case. , 1998, 55, 215-218.		35
272	Lack of Susceptibility of Bicyclic Nucleoside Analogs, Highly Potent Inhibitors of Varicella-Zoster Virus, to the Catabolic Action of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase. Molecular Pharmacology, 2002, 61, 1140-1145.	1.0	35
273	Design and synthesis of bioactive 1,2-annulated adamantane derivatives. Organic and Biomolecular Chemistry, 2008, 6, 3177.	1.5	35
274	Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors. Current Medicinal Chemistry, 2014, 21, 1956-1967.	1.2	35
275	Synthesis of adamantane spiro sultones as potential antiviral agents. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 647-648.	1.0	34
276	Hept Derivatives: 6-Benzyl-1-ethoxymethyl-5-isopropyluracil (MKC-442). Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 575-583.	0.4	34
277	Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino-acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184. FEBS Journal, 2000, 267, 2658-2665.	0.2	34
278	Hiv-1 Specific Reverse Transcriptase Inhibitors: why are Tsao-Nucleosides so Unique?. Journal of Carbohydrate Chemistry, 2000, 19, 451-469.	0.4	34
279	From adefovir to Atriplaâ„¢ via tenofovir, Vireadâ„¢ and Truvadaâ„¢. Future Virology, 2006, 1, 709-715.	0.9	34
280	Dancing with chemical formulae of antivirals: A panoramic view (Part 2). Biochemical Pharmacology, 2013, 86, 1397-1410.	2.0	34
281	Organic Chemist Whose Inventions Reshaped the Antiviral Drug World. Medicinal Research Reviews, 2013, 33, 1-2.	5.0	34
282	Synthesis, antimicrobial, anticancer, antiviral evaluation and QSAR studies of 4-(1-aryl-2-oxo-1,2-dihydro-indol-3-ylideneamino)-N-substituted benzene sulfonamides. Arabian Journal of Chemistry, 2014, 7, 396-408.	2.3	34
283	Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase. FEBS Letters, 2000, 483, 181-185.	1.3	33
284	Three decades of antiviral drugs. Nature Reviews Drug Discovery, 2007, 6, 941-941.	21.5	33
285	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4601-4605.	1.4	33
286	Escape of Tick-Borne Flavivirus from 2â€²- C -Methylated Nucleoside Antivirals Is Mediated by a Single Conservative Mutation in NS5 That Has a Dramatic Effect on Viral Fitness. Journal of Virology, 2017, 91, .	1.5	33
287	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. Journal of Medicinal Chemistry, 2021, 64, 4239-4256.	2.9	33
288	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 3729-3757.	2.9	33

#	Article	IF	Citations
289	Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. Journal of Medical Virology, 1993, 39, 167-172.	2.5	32
290	Potential Multifunctional Inhibitors of HIV-1 Reverse Transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] Heterodimers Modified in the Linker and in the Dideoxynucleoside Region. Journal of Medicinal Chemistry, 1999, 42, 5188-5196.	2.9	32
291	Historical Perspectives in the Development of Antiviral Agents Against Poxviruses. Viruses, 2010, 2, 1322-1339.	1.5	32
292	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the â€œNNRTI Adjacentâ€• Binding Site. ACS Medicinal Chemistry Letters, 2018, 9, 334-338.	1.3	32
293	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles. Journal of Medicinal Chemistry, 2019, 62, 11430-11436.	2.9	32
294	1-Î²-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-Î²-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2â€²,3â€²-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes. Biochemical and Biophysical Research Communications, 1991, 178, 563-569.	1.0	31
295	New developments in anti-HIV chemotherapy. Il Farmaco, 2001, 56, 3-12.	0.9	31
296	In search of effective anti-HHV-6 agents. Journal of Clinical Virology, 2006, 37, S82-S86.	1.6	31
297	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1210-1214.	2.6	31
298	Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines. European Journal of Medicinal Chemistry, 2010, 45, 5022-5030.	2.6	31
299	Dancing with chemical formulae of antivirals: A personal account. Biochemical Pharmacology, 2013, 86, 711-725.	2.0	31
300	5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. European Journal of Medicinal Chemistry, 2018, 155, 714-724.	2.6	31
301	Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharmaceutica Sinica B, 2022, 12, 1567-1590.	5.7	31
302	Trends in the disease burden of HBV and HCV infection in China from 1990-2019. International Journal of Infectious Diseases, 2022, 122, 476-485.	1.5	31
303	Inhibitory effects of 9-(2-Phosphonylmethoxyethyl)adenine and 3â€²-azido-2â€²,3â€²-dideoxythymidine on tumor development in mice inoculated intracerebrally with moloney murine sarcoma virus. International Journal of Cancer, 1990, 45, 486-489.	2.3	30
304	Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. Antiviral Research, 1991, 16, 1-9.	1.9	30
305	Activity of the keggin polyoxotungstate pm-19 against herpes simplex virus type 2 infection in immunosuppressed mice: Role of peritoneal macrophage activation. Journal of Medical Virology, 1993, 41, 191-195.	2.5	30
306	Antiviral Metal Complexes. Metal-Based Drugs, 1997, 4, 173-192.	3.8	30

#	Article	IF	Citations
307	Antivirals: current state of the art. Future Virology, 2008, 3, 393-405.	0.9	30
308	Chapter 1 Looking Back in 2009 at the Dawning of Antiviral Therapy Now 50 Years Ago. Advances in Virus Research, 2009, 73, 1-53.	0.9	30
309	Human viral diseases: what is next for antiviral drug discovery?. Current Opinion in Virology, 2012, 2, 572-579.	2.6	30
310	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. European Journal of Medicinal Chemistry, 2017, 130, 209-222.	2.6	30
311	Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. ACS Medicinal Chemistry Letters, 2017, 8, 1188-1193.	1.3	30
312	An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice. Journal of Virology, 2019, 93, .	1.5	30
313	[32] Interferon induction by polynucleotides, modified polynucleotides, and polycarboxylates. Methods in Enzymology, 1981, 78, 227-236.	0.4	29
314	SYNTHESIS OF 1-(2-DEOXY-Î²-D- RIBOFURANOSYL)-2,4-DIFLUORO-5-SUBSTITUTED-BENZENE THYMIDINE MIMICS,*SOME RELATED Î±-ANOMERS, AND THEIR EVALUATION AS ANTIVIRAL AND ANTICANCER AGENTS. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 11-40.	0.4	29
315	Systemic Cidofovir in Papillomatosis. Clinical Infectious Diseases, 2001, 32, e62-e64.	2.9	29
316	Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. European Journal of Medicinal Chemistry, 2014, 80, 112-121.	2.6	29
317	Novel 3,5-bis(arylidene)-4-oxo-1-piperidinyl dimers: Structureâ€“activity relationships and potent antileukemic and antilymphoma cytotoxicity. European Journal of Medicinal Chemistry, 2014, 77, 315-322.	2.6	29
318	Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Acta Pharmaceutica Sinica B, 2020, 10, 344-357.	5.7	29
319	Interferon Induction by a 2'-Modified Double-Helical RNA, Poly(2'-azido-2'-deoxyinosinic acid) . polycytidylic acid. FEBS Journal, 1978, 88, 341-349.	0.2	28
320	Synthesis and antiviral activity of acyclic analogues of 1,5-anhydrohexitol nucleosides using Mitsunobu reaction. Tetrahedron, 1996, 52, 13655-13670.	1.0	28
321	Enantioselective synthesis of homocarbocyclic-2â€²-oxo-3â€²-azanucleosides. Tetrahedron, 2006, 62, 1171-1181.	1.0	28
322	Inhibitory Activities of Three Classes of Acyclic Nucleoside Phosphonates against Murine Polyomavirus and Primate Simian Virus 40 Strains. Antimicrobial Agents and Chemotherapy, 2007, 51, 2268-2273.	1.4	28
323	Synthesis of novel PETT analogues: 3,4-dimethoxy phenyl ethyl 1,3,5-triazinyl thiourea derivatives and their antibacterial and anti-HIV studies. Journal of the Brazilian Chemical Society, 2007, 18, .	0.6	28
324	Lead Optimization of Diarylpyrimidines as Nonâ€nucleoside Inhibitors of HIVâ€1 Reverse Transcriptase. ChemMedChem, 2010, 5, 837-840.	1.6	28

#	Article	IF	Citations
325	Synthesis of thiocarbohydrazide and carbohydrazide derivatives as possible biologically active agents. Medicinal Chemistry Research, 2014, 23, 1046-1056.	1.1	28
326	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2014, 82, 600-611.	2.6	28
327	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 109, 294-304.	2.6	28
328	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 370-375.	1.3	28
329	Molecular design opportunities presented by solventâ€exposed regions of target proteins. Medicinal Research Reviews, 2019, 39, 2194-2238.	5.0	28
330	Mechanism of the Antiviral Activity Resulting from Sequential Administration of Complementary Homopolyribonucleotides to Cell Cultures. Journal of Virology, 1972, 9, 721-731.	1.5	28
331	Antiviral and Non-antiviral Activity of Highly Purified Interferon. Nature: New Biology, 1973, 246, 141-143.	4.5	27
332	Selective antiherpetic activity of carbocyclic analogues of (E)-5-(2-halogenovinyl)-2â€²-deoxyuridines: Dependence on specific phosphorylation by viral thymidine kinase. Biochemical and Biophysical Research Communications, 1985, 126, 397-403.	1.0	27
333	S-Adenosyl-L-homocysteine Hydrolase Inhibitors as Anti-Viral Agents: 5â€²-Deoxyaristeromycin. Nucleosides & Nucleotides, 1993, 12, 185-198.	0.5	27
334	5-(Acylethynyl)uracils, 5-(Acylethynyl)-2'-deoxyuridines and 5-(Acylethynyl)-1-(2-hydroxyethoxy)methyluracils. Their synthesis, antiviral and cytotoxic activities11Part 25 of our series of studies on uracil derivatives and analogues. For part 24, see [1]. European Journal of Medicinal Chemistry, 1999, 34, 389-398.	2.6	27
335	Potent inhibition of hemangiosarcoma development in mice by cidofovir. International Journal of Cancer, 2001, 92, 161-167.	2.3	27
336	Antiviral Activity of Cyclosaligenyl Prodrugs of Acyclovir, Carbovir and Abacavir. Antiviral Chemistry and Chemotherapy, 2001, 12, 301-306.	0.3	27
337	Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiology, 2003, 3, 25.	1.3	27
338	Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. Journal of Antimicrobial Chemotherapy, 2006, 59, 80-86.	1.3	27
339	Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions. Medicinal Research Reviews, 2010, 30, 667-707.	5.0	27
340	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 121, 352-363.	2.6	27
341	Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential. Current Medicinal Chemistry, 2015, 22, 3866-3880.	1.2	27
342	Degradation of Poly(inosinic acid) . poly(cytidylic acid) [(I)n . (Cn)] by Human Plasma. FEBS Journal, 1979, 93, 165-172.	0.2	26

#	Article	IF	Citations
343	Nucleic acid related compounds. 53. Synthesis and biological evaluation of 2â€²-deoxy-Î²-threo-pentofuranosyl nucleosides. "Reversion to starting alcohol" in Barton-type reductions of thionocarbonates. Canadian Journal of Chemistry, 1988, 66, 1258-1262.	0.6	26
344	Diaryl phosphate derivatives act as pro-drugs of AZT with reduced cytotoxicity compared to the parent nucleoside. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 427-430.	1.0	26
345	Novel Potential Agents for Human Cytomegalovirus Infection:â€‰ Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. Journal of Medicinal Chemistry, 1999, 42, 1145-1150.	2.9	26
346	Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Research, 2004, 64, 17-25.	1.9	26
347	ANTI-HIV CHEMOTHERAPY: CURRENT STATE OF THE ART. Medicinal Chemistry Research, 2004, 13, 439-478.	1.1	26
348	(S)â€9â€(3â€hydroxyâ€2â€phosphonylmethoxypropyl)adenine [(S)â€HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo. Tropical Medicine and International Health, 1996, 1, 255-263.	1.0	26
349	2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles: Synthesis, cytotoxic activity and mechanism of action. European Journal of Medicinal Chemistry, 2014, 84, 687-697.	2.6	26
350	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. European Journal of Medicinal Chemistry, 2015, 102, 167-179.	2.6	26
351	Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored â€œhydrophobic channelâ€. Organic and Biomolecular Chemistry, 2018, 16, 1014-1028.	1.5	26
352	Molecular Hybridization-Inspired Optimization of Diarylbenzopyrimidines as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors with Improved Activity against K103N and E138K Mutants and Pharmacokinetic Profiles. ACS Infectious Diseases, 2020, 6, 787-801.	1.8	26
353	Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatology International, 2020, 14, 212-224.	1.9	26
354	Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. Journal of General Virology, 2002, 83, 1887-1896.	1.3	26
355	Poly(rI) more important than poly(rC) in the interferon induction process by poly(rI)Â·poly(rC). Virology, 1973, 54, 278-282.	1.1	25
356	Non-antiviral activities of interferon are not controlled by chromosome 21. Nature, 1975, 256, 132-134.	13.7	25
357	[25] Analysis of inhibition of retroviral reverse transcriptase. Methods in Enzymology, 1996, 275, 472-502.	0.4	25
358	Therapeutic Potential of HPMPC (Cidofovir), PMEA (Adefovir) and Related Acyclic Nucleoside Phosphonate Analogues as Broad-Spectrum Anttviral Agents. Nucleosides & Nucleotides, 1997, 16, 983-992.	0.5	25
359	Discovery of small molecular inhibitors targeting HIV-1 gp120â€“CD4 interaction drived from BMS-378806. European Journal of Medicinal Chemistry, 2014, 86, 481-490.	2.6	25
360	Chemotherapy of respiratory syncytial virus infections: the final breakthrough. International Journal of Antimicrobial Agents, 2015, 45, 234-237.	1.1	25

#	Article	IF	Citations
361	Hybrid chemistry. Part 4: Discovery of etravirineâ€“VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 4248-4255.	1.4	25
362	Anti-HIV diarylpyrimidineâ€“quinolone hybrids and their mode of action. Bioorganic and Medicinal Chemistry, 2015, 23, 3860-3868.	1.4	25
363	Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors. Chinese Chemical Letters, 2020, 31, 764-768.	4.8	25
364	Clinical characteristics of older and younger patients infected with SARS-CoV-2. Aging, 2020, 12, 11296-11305.	1.4	25
365	Chromosome 21 does not code for an interferon receptor. Nature, 1976, 264, 249-251.	13.7	24
366	Synthesis and biological evaluation of phosphonopyrimidine and phosphonopurine ribonucleosides.. Chemical and Pharmaceutical Bulletin, 1987, 35, 3227-3234.	0.6	24
367	Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents. Current Eye Research, 1991, 10, 193-199.	0.7	24
368	Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Expert Opinion on Investigational Drugs, 1994, 3, 253-271.	1.9	24
369	Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2â€²-deoxyuridine. Journal of Cancer Research and Clinical Oncology, 1994, 120, 545-549.	1.2	24
370	Synthesis and Antiviral Activity of Acyclic Nucleotide Analogues Derived from 6-(Aminomethyl)purines and Purine-6-carboxamidines. Collection of Czechoslovak Chemical Communications, 1996, 61, 1525-1537.	1.0	24
371	Synthesis and anti-HIV activity of a bile acid analog of cosalane. Tetrahedron, 2001, 57, 9385-9391.	1.0	24
372	Acute Encephalitis, a Poliomyelitisâ€like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections. Brain Pathology, 2003, 13, 279-290.	2.1	24
373	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Communications Chemistry, 2019, 2, .	2.0	24
374	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2019, 27, 447-456.	1.4	24
375	Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharmaceutical Research, 1999, 16, 1035-1040.	1.7	23
376	Hamao Umezawa Memorial Award Lecture11Delivered by the author at the Twenty-second International Congress of Chemotherapy, Amsterdam, The Netherlands (30 Juneâ€“3 July 2001).. International Journal of Antimicrobial Agents, 2001, 18, 309-328.	1.1	23
377	Synthesis and anti-HIV activity evaluation of novel Nâ€²-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Medicinal Chemistry Research, 2010, 19, 652-663.	1.1	23
378	Alkoxyâ€5â€nitrosopyrimidines: Useful Building Block for the Generation of Biologically Active Compounds. European Journal of Organic Chemistry, 2010, 2010, 3823-3830.	1.2	23

#	Article	IF	Citations
379	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2011, 19, 7093-7099.	1.4	23
380	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2015, 97, 1-9.	2.6	23
381	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue. European Journal of Medicinal Chemistry, 2015, 102, 215-222.	2.6	23
382	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities. Bioorganic and Medicinal Chemistry, 2015, 23, 6587-6593.	1.4	23
383	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2017, 25, 4397-4406.	1.4	23
384	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. European Journal of Medicinal Chemistry, 2020, 193, 112237.	2.6	23
385	Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. Immunity and Ageing, 2022, 19, 12.	1.8	23
386	Structureâ€“Activity of Inhibition of HIV-1 Integrase and Virus Replication by G-quartet Oligonucleotides. DNA and Cell Biology, 2001, 20, 499-508.	0.9	22
387	Nitroimidazoles, part 4: Synthesis and anti-HIV activity of new 5-alkylsulfanyl and 5-(4â€²-arylsulfonyl)piperazinyl-4-nitroimidazole derivatives. Heteroatom Chemistry, 2007, 18, 333-340.	0.4	22
388	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2019, 182, 111603.	2.6	22
389	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. Biomedicines, 2021, 9, 412.	1.4	22
390	Interferon Production Linked to Toxicity of Polyriboinosinic Acid-Polyribocytidylic Acid. Infection and Immunity, 1972, 6, 344-347.	1.0	22
391	Anti-HIV Derivatives of 1-(2,3-Dideoxy-3-N-hydroxyamino-Î²-D-threo-pentofuranosyl)thymine. Nucleosides & Nucleotides, 1994, 13, 1871-1889.	0.5	21
392	Polyanion Inhibitors of Human Immunodeficiency Virus and Other Viruses. 6. Micelle-like Anti-HIV Polyanionic Compounds Based on a Carbohydrate Core. Journal of Medicinal Chemistry, 1997, 40, 350-356.	2.9	21
393	Retinoic Acid Conjugates as Potential Antitumor Agents:Â Synthesis and Biological Activity of Conjugates with Ara-A, Ara-C, 3(2H)-Furanone, and Aniline Mustard Moieties. Journal of Medicinal Chemistry, 1997, 40, 3851-3857.	2.9	21
394	Inhibition of Human Immunodeficiency Virus Type (HIV-1) Replication by some Diversely Functionalized Spirocyclopropyl Derivatives. Archiv Der Pharmazie, 1999, 332, 163-166.	2.1	21
395	New developments in anti-HIV chemotherapy. Pure and Applied Chemistry, 2001, 73, 55-66.	0.9	21
396	Synthesis and stereochemical characterisation of platinum(II) complexes with the antiviral agents penciclovir and famciclovir. Inorganica Chimica Acta, 2003, 344, 174-182.	1.2	21

#	Article	IF	Citations
397	Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives. Arkivoc, 2006, 2006, 109-118.	0.3	21
398	Interferon and Its Inducersâ€"A Never-Ending Story: â€œOldâ€•and â€œNewâ€•Data in a New Perspective. Journal of Infectious Diseases, 2006, 194, S19-S26.	1.9	21
399	Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine. Biochemical Pharmacology, 2008, 76, 997-1005.	2.0	21
400	Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1016-1023.	2.6	21
401	Tenofovir: Quo Vadis Anno 2012 (Where Is It Going in the Year 2012)?. Medicinal Research Reviews, 2012, 32, 765-785.	5.0	21
402	Multivalent Agents: A Novel Concept and Preliminary Practice in Anti-HIV Drug Discovery. Current Medicinal Chemistry, 2013, 20, 815-832.	1.2	21
403	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2014, 22, 633-642.	1.4	21
404	Synthesis and evaluation of the biological activity of Nâ€²-[2-oxo-1,2 dihydro-3H-indol-3-ylidene] benzohydrazides as potential anticancer agents. RSC Advances, 2015, 5, 45492-45501.	1.7	21
405	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 115, 53-62.	2.6	21
406	Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains. Bioorganic Chemistry, 2019, 89, 102974.	2.0	21
407	Interferon Inducers. Antibiotics and Chemotherapy, 1980, 27, 251-287.	0.5	20
408	Targets for the Antiviral and Antitumor Activities of Nucleoside, Nucleotide and Oligonucleotide Analogues. Nucleosides & Nucleotides, 1985, 4, 3-11.	0.5	20
409	Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster virus strains.. Tohoku Journal of Experimental Medicine, 1986, 148, 275-283.	0.5	20
410	Structure investigation and anti-HIV activities of high-molecular weight ATA polymers. Journal of Organic Chemistry, 1992, 57, 7241-7248.	1.7	20
411	Homo Dinucleoside-Î±-hydroxyphosphonate Diesters as Prodrugs of the Antiviral Nucleoside Analogues 2',3'-Dideoxythymidine and 3'-Azido-2',3'-dideoxythymidine. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 759-762.	0.4	20
412	Synthesis and antiviral activity of 2-deoxy-1,5-anhydro-D-mannitol nucleosides containing a pyrimidine base moiety. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1457-1460.	1.0	20
413	Recent developments in the chemotherapy of HIV infections. Pure and Applied Chemistry, 1998, 70, 567-577.	0.9	20
414	The Unabated Synthesis of New Nucleoside Analogues with Antiviral Potential: A Tribute to Morris J. Robins. Nucleosides, Nucleotides and Nucleic Acids, 2009, 28, 586-600.	0.4	20

#	Article	IF	Citations
415	Anti-HIV, antimycobacterial and antimicrobial studies of newly synthesized 1,2,4-triazole clubbed benzothiazoles. Medicinal Chemistry Research, 2013, 22, 1320-1329.	1.1	20
416	Interferon Induction by Two 2'-Modified Double-Helical RNAs, Poly(2'-nuoro-2'-deoxymosimc acid) . poly(cytidylic acid) and Poly(2'-chloro-2'-deoxyinosinic acid) . poly(cytidylic acid). FEBS Journal, 1980, 107, 279-288.	0.2	19
417	Flow cytometric method to monitor the destruction of CD4+ cells following their fusion with HIV-infected cells. Cytometry, 1990, 11, 736-743.	1.8	19
418	Lithiation of Uracilnucleosides and its Application to the Synthesis of a New Class of Anti-HIV-1 Acyclonucleosides. Nucleosides & Nucleotides, 1991, 10, 397-400.	0.5	19
419	Synthesis of 2â€carbamoylmethylâ€6â€Î²â€Dâ€ribofuranosylpyridine with the aid of a Pd(0)â€catalyzed reaction. Journal of Heterocyclic Chemistry, 1993, 30, 1245-1252.	1.4	19
420	Ribosylation of Pyrimidine 2â€²-Deoxynucleosides. Nucleosides & Nucleotides, 1996, 15, 1323-1334.	0.5	19
421	Synthesis of 3â€²-C-branched 1â€²,5â€²-anhydromannitol nucleosides as new antiherpes agents. Tetrahedron, 1998, 54, 2209-2226.	1.0	19
422	Ten Paths to the Discovery of Antivirally Active Nucleoside and Nucleotide Analogues. Nucleosides, Nucleotides and Nucleic Acids, 2012, 31, 339-352.	0.4	19
423	The HolÃ½ Trinity. Advances in Pharmacology, 2013, 67, 293-316.	1.2	19
424	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. European Journal of Medicinal Chemistry, 2014, 76, 531-538.	2.6	19
425	Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy . Drug Design, Development and Therapy, 2020, Volume 14, 2759-2774.	2.0	19
426	Synthesis and Biological Activity of the Mono- and Diamino Analogues of 2â€²-Deoxyadenosine, Cordycepin, 9-(3-Deoxy-Î±-D-Threo-Pentofuranosyl)-Adenine (A Structural Component of Agrocin 84) and 9-(2-Deoxy-Î±-D-Threo-Pentofuranosyl)Adenine. Nucleosides & Nucleotides, 1989, 8, 1231-1257.	0.5	18
427	Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?. International Journal of Antimicrobial Agents, 1997, 9, 21-36.	1.1	18
428	Anti-(herpes simplex virus) activity of 4â€²-thio-2â€²-deoxyuridines: a biochemical investigation for viral and cellular target enzymes. Biochemical Journal, 2000, 351, 319-326.	1.7	18
429	A Thymidine Phosphorylase-Stable Analogue of BVDU with Significant Antiviral Activity. Journal of Medicinal Chemistry, 2002, 45, 5426-5429.	2.9	18
430	The race for interferonâ€free HCV therapies: a snapshot by the spring of 2012. Reviews in Medical Virology, 2012, 22, 392-411.	3.9	18
431	Antiproliferative and Antiviral Activity of Three Libraries of Adamantane Derivatives. Archiv Der Pharmazie, 2014, 347, 334-340.	2.1	18
432	Design, Synthesis, and Antiâ€<scp>HIV</scp> Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the <scp>NNRTI</scp> Binding Pocket. Chemical Biology and Drug Design, 2015, 86, 122-128.	1.5	18

#	Article	IF	Citations
433	Synthesis, properties, and biological activity of some nucleoside cyclic phosphoramidates. Journal of the Chemical Society Perkin Transactions 1, 1984, , 1471.	0.9	17
434	The chemistry of 2' ,3'-seconucleosides II. Reactions and biological properties of 2',3'-secopyrimidine ribonucleosides. Tetrahedron, 1985, 41, 5965-5972.	1.0	17
435	Synthesis of 3-Nitrosoimidazo[1,2-a]pyridine Derivatives as Potential Antiretroviral Agents. Archiv Der Pharmazie, 2001, 334, 224-228.	2.1	17
436	Anti-herpesvirus activity of (1â€²S,2â€²R)-9-[[1â€²,2â€²-bis(hydroxymethyl)-cycloprop-1â€²-yl]methyl]guanine (A-5021) in vitro and in vivo. Antiviral Research, 2001, 49, 115-120.	1.9	17
437	Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile 2006 (1st Edition). Antiviral Chemistry and Chemotherapy, 2006, 17, 113-114.	0.3	17
438	Synthesis and Biological Evaluation of a Series of 2â€((1â€substitutedâ€1<i>H</i>â€1,2,3â€triazolâ€4â€yl)methylthio)â€6â€(naphthalenâ€1â€ylmethyl)pyrimidinâ€4(3<i>H</i>)â€one Potential <scp>HIV</scp>â€1 Inhibitors. Chemical Biology and Drug Design, 2015, 86, 614-618.	1.5	17
439	Synthesis and Preliminary Antiviral Activities of Piperidineâ€substituted Purines against <scp>HIV</scp> and Influenza A/H1N1 Infections. Chemical Biology and Drug Design, 2015, 86, 568-577.	1.5	17
440	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. European Journal of Medicinal Chemistry, 2017, 126, 190-201.	2.6	17
441	Remdesivir: Quo vadis?. Biochemical Pharmacology, 2021, 193, 114800.	2.0	17
442	Synthesis and Biological Evaluation of a Series of Substituted 2-Pyridine C-Nucleosides. Nucleosides & Nucleotides, 1985, 4, 523-538.	0.5	16
443	Recent trends and development in antiviral chemotherapy. Antiviral Research, 1985, 5, 11-19.	1.9	16
444	Assessment of thein vitro broad-spectrum antiviral activity of some selected antitumor organotin complexes. Applied Organometallic Chemistry, 1989, 3, 431-436.	1.7	16
445	New 1,2,6-thiadiazine dioxide acyclonucleosides: Synthesis and antiviral evaluation. Bioorganic and Medicinal Chemistry, 1995, 3, 1527-1535.	1.4	16
446	Imidazothiadiazine dioxides: synthesis and antiviral activity. Bioorganic and Medicinal Chemistry, 1999, 7, 1617-1623.	1.4	16
447	Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2. Biochemical Journal, 2000, 351, 167-171.	1.7	16
448	Nucleoside Analogues Exerting Antiviral Activity Through a Nonâ€nucleoside Mechanism. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 457-470.	0.4	16
449	Synthesis and biological evaluation of 5-(alkyn-1-yl)-1-(p-toluenesulfonyl)uracil derivatives. Canadian Journal of Chemistry, 2006, 84, 580-586.	0.6	16
450	Viral DNA Polymerase Inhibitors. , 2009, , 481-526.		16

#	Article	IF	Citations
451	Nicotinic Acid Benzylidene/Phenyl-Ethylidene Hydrazides: Synthesis, Antimicrobial Evaluation and QSAR Studies. Letters in Drug Design and Discovery, 2011, 8, 733-749.	0.4	16
452	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 3220-3226.	1.4	16
453	Different Heterocycles Functionalized sâ€Triazine Analogues: Design, Synthesis and In Vitro Antimicrobial, Antituberculosis, and Antiâ€HIV Assessment. Journal of Heterocyclic Chemistry, 2014, 51, 1641-1658.	1.4	16
454	Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. Reviews in Medical Virology, 2015, 25, 254-267.	3.9	16
455	3,5-Bis(3-alkylaminomethyl-4-hydroxybenzylidene)-4-piperidones: A Novel Class of Potent Tumor-Selective Cytotoxins. Journal of Medicinal Chemistry, 2016, 59, 763-769.	2.9	16
456	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. Bioorganic and Medicinal Chemistry, 2017, 25, 5779-5789.	1.4	16
457	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3491-3495.	1.0	16
458	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. Chemical Biology and Drug Design, 2018, 92, 2009-2021.	1.5	16
459	Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. European Journal of Medicinal Chemistry, 2019, 182, 111619.	2.6	16
460	Design, synthesis, and biological evaluation of piperidinylâ€substituted [1,2,4]triazolo[1,5â€a]pyrimidine derivatives as potential antiâ€HIVâ€1 agents with reduced cytotoxicity. Chemical Biology and Drug Design, 2021, 97, 67-76.	1.5	16
461	Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. Chinese Chemical Letters, 2021, 32, 4053-4057.	4.8	16
462	Design and Synthesis of Regioisomeric Analogues of a Specific Anti-HIV-1 Agent 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Nucleosides & Nucleotides, 1994, 13, 155-162.	0.5	15
463	Antiviral activity of ganciclovir elaidic acid ester against herpesviruses. Antiviral Research, 2000, 45, 157-167.	1.9	15
464	CXCR4 is the primary receptor for feline immunodeficiency virus in astrocytes. Journal of NeuroVirology, 2001, 7, 487-492.	1.0	15
465	Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid. FEBS Journal, 1988, 177, 91-96.	0.2	15
466	Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors. Mini-Reviews in Medicinal Chemistry, 2009, 9, 510-518.	1.1	15
467	Current treatment of hepatitis B virus infections. Reviews in Medical Virology, 2015, 25, 354-365.	3.9	15
468	Curious Discoveries in Antiviral Drug Development: The Role of Serendipity. Medicinal Research Reviews, 2015, 35, 698-719.	5.0	15

#	Article	IF	Citations
469	Synthesis, and prediction of molecular properties and antimicrobial activity of some acylhydrazones derived from N-(arylsulfonyl)methionine. Turkish Journal of Chemistry, 2016, 40, 510-534.	0.5	15
470	Design, synthesis, and evaluation of â€œdual-siteâ€•binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2021, 211, 113063.	2.6	15
471	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. European Journal of Medicinal Chemistry, 2021, 213, 113051.	2.6	15
472	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs. Journal of Medicinal Chemistry, 2021, 64, 10297-10311.	2.9	15
473	Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. European Journal of Medicinal Chemistry, 2021, 226, 113848.	2.6	15
474	Pyrimidine Nucleoside Analogues as Antiviral Agents. , 1984, , 203-230.		15
475	In search of specific inhibitors of retrovirus replication. Antiviral Research, 1985, 5, 89-94.	1.9	14
476	A Methylated Derivative of 5â€˜-Noraristeromycin. Journal of Organic Chemistry, 1997, 62, 5645-5646.	1.7	14
477	Benzothiadiazine dioxide acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1031-1032.	1.0	14
478	Synthesis and Anti-HIV Activity of Cosalane Analogues with Substituted Benzoic Acid Rings Attached to the Pharmacophore through Methylene and Amide Linkers. Journal of Organic Chemistry, 1999, 64, 5858-5866.	1.7	14
479	Enhancing the aqueous solubility of d4T-based phosphoramidate prodrugs. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 381-384.	1.0	14
480	Design, Synthesis and Biological Evaluation of Novel Curcumin Analogues as Anti-Neoplastic Agents. Letters in Drug Design and Discovery, 2006, 3, 304-310.	0.4	14
481	Sydnone Sulfonamide Derivatives as Antibacterial, Antifungal, Antiproliferative and Anti-HIV Agents. Pharmaceutical Chemistry Journal, 2014, 48, 260-268.	0.3	14
482	An Odyssey in antiviral drug developmentâ€”50 years at the Rega Institute: 1964â€“2014. Acta Pharmaceutica Sinica B, 2015, 5, 520-543.	5.7	14
483	TanoveaÂ® for the treatment of lymphoma in dogs. Biochemical Pharmacology, 2018, 154, 265-269.	2.0	14
484	Design, synthesis, and biologic evaluation of novel galloyl derivatives as <scp>HIV</scp>â€1 <scp>RN</scp>ase H inhibitors. Chemical Biology and Drug Design, 2019, 93, 582-589.	1.5	14
485	Privileged scaffold inspired design of novel oxime-biphenyl-DAPYs in treatment of HIV-1. Bioorganic Chemistry, 2020, 99, 103825.	2.0	14
486	Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. Journal of Medicinal Chemistry, 2021, 64, 13658-13675.	2.9	14

#	Article	IF	Citations
487	Protection of Rabbits Against Local Vaccinia Virus Infection by Brucella abortus and Polyacrylic Acid in the Absence of Systemic Interferon Production. Infection and Immunity, 1973, 8, 669-673.	1.0	14
488	Synthesis and Anti-HIV Evaluation of Novel 1,2,4-triazole Derivatives as Potential Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. Letters in Drug Design and Discovery, 2013, 10, 27-34.	0.4	14
489	Gliotoxin analogs as inhibitors of reverse transcriptase. 2. Resolution and x-ray crystal structure determination. Journal of Medicinal Chemistry, 1978, 21, 799-804.	2.9	13
490	Antiviral Activity Spectrum of Nucleoside and Nucleotide Analogues. Nucleosides & Nucleotides, 1991, 10, 167-180.	0.5	13
491	Chemical crosslinking of the subunits of HIVâ€1 reverse transcriptase. Protein Science, 1996, 5, 278-286.	3.1	13
492	Novel Carbocyclic Nucleosides Containing A Cyclobutyl Ring. Guanosine and Adenosine Analogues. Nucleosides & Nucleotides, 1998, 17, 1237-1253.	0.5	13
493	In vitro Activity of Polyhydroxycarboxylates against Herpesviruses and Hiv. Antiviral Chemistry and Chemotherapy, 2001, 12, 337-345.	0.3	13
494	Synthesis, structural characterisation and biological activity of Zn(II) and Pd(II) complexes of 3-substituted 5-(2â€²-pyridyl)-1,4-benzodiazepin-2-one derivatives. Polyhedron, 2002, 21, 2567-2577.	1.0	13
495	Î·6-(Arene)tricarbonylchromium and Manganese Complexes Linked to 2â€˜-Deoxyuridine. Organometallics, 2007, 26, 5727-5730.	1.1	13
496	Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Part 13. Chemistry and Biodiversity, 2009, 6, 561-568.	1.0	13
497	Acyclic nucleoside phosphonates: An unfinished story. Collection of Czechoslovak Chemical Communications, 2011, 76, 829-842.	1.0	13
498	Synthesis and Evaluation of Novel 4â€Substituted Styryl Quinazolines as Potential Antimicrobial Agents. Archiv Der Pharmazie, 2012, 345, 964-972.	2.1	13
499	Synthesis and biological evaluation of DAPYâ€“DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic and Medicinal Chemistry, 2015, 23, 624-631.	1.4	13
500	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1348-1351.	1.0	13
501	Discovery of potent <scp>HIV</scp>â€1 nonâ€nucleoside reverse transcriptase inhibitors by exploring the structureâ€“activity relationship of solventâ€exposed regions I. Chemical Biology and Drug Design, 2019, 93, 430-437.	1.5	13
502	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2020, 202, 112549.	2.6	13
503	Broad-Spectrum Antiviral Activity of 3â€²-Deoxy-3â€²-Fluoroadenosine against Emerging Flaviviruses. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	13
504	Antiviral activity of a chemically stabilized 2-5A analog upon microinjection into HeLa cells. FEBS Letters, 1986, 198, 326-332.	1.3	12

#	Article	IF	Citations
505	Specific HIV-1 Reverse Transcriptase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 47-53.	0.5	12
506	Synthesis and Antiviral and Cytostatic Activities of Carbocyclic Nucleosides Incorporating a Modified Cyclobutane Ring. Archiv Der Pharmazie, 1999, 332, 348-352.	2.1	12
507	3-Benzamido, Ureido and Thioureidoimidazo[1,2-a]pyridine Derivatives as Potential Antiviral Agents.. Chemical and Pharmaceutical Bulletin, 2001, 49, 1631-1635.	0.6	12
508	Synthesis, spectroscopic characterization, antineoplastic, inÂvitro-cytotoxic, and antibacterial activities of mononuclear ruthenium(II) complexes. Journal of Coordination Chemistry, 2012, 65, 823-839.	0.8	12
509	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 2535-2541.	1.4	12
510	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2016, 24, 4424-4433.	1.4	12
511	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5â€b]pyridinâ€2â€ylthioacetanilides as Potent HIV NNRTIs Via a Structureâ€based Bioisosterism Approach. Chemical Biology and Drug Design, 2016, 88, 241-253.	1.5	12
512	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. European Journal of Medicinal Chemistry, 2017, 140, 383-391.	2.6	12
513	Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. Bioorganic and Medicinal Chemistry, 2019, 27, 3836-3845.	1.4	12
514	Structureâ€“Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. ACS Infectious Diseases, 2020, 6, 2225-2234.	1.8	12
515	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring. Journal of Medicinal Chemistry, 2021, 64, 5067-5081.	2.9	12
516	Increased Toxicity of Double-Stranded Ribonucleic Acid in Virus-Infected Animals. Infection and Immunity, 1973, 7, 167-172.	1.0	12
517	Protective effects of anionic detergents on interferons: Reversible denaturation. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1974, 359, 364-368.	1.7	11
518	Synthesis of 2â€²,3â€²-dideoxy-3-isoadenosine: a new structural analogue of the anti-HIV active compound, 2â€²,3â€²-dideoxyadenosine. Journal of the Chemical Society Chemical Communications, 1991, , 1650-1651.	2.0	11
519	Synthesis and antiproliferative activity of 2â€²-O-allyl-1-Î²-D-arabinofuranosyl-uracil, -cytosine and -adenine. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 473-478.	1.0	11
520	The Emerging Role of Fusion Inhibitors in HIV Infection. Drugs in R and D, 1999, 2, 321-331.	1.1	11
521	In vitro evaluation of the effect of temporary removal of HIV drug pressure. Antiviral Research, 2000, 46, 215-221.	1.9	11
522	Highly Stereoselective Synthesis and Biological Properties of Nucleoside Analogues Bearing a Spiro Inserted Oxirane Ring. Nucleosides, Nucleotides and Nucleic Acids, 2000, 19, 775-794.	0.4	11

#	Article	IF	Citations
523	Phosphoramidate Derivatives of Stavudine as Inhibitors of HIV: Unnatural Amino Acids May Substitute for Alanine. Antiviral Chemistry and Chemotherapy, 2000, 11, 111-116.	0.3	11
524	Synthesis of 1,2-annulated adamantane heterocycles: structural determination studies of a bioactive cyclic sulfite. Tetrahedron Letters, 2009, 50, 2671-2675.	0.7	11
525	Synthesis of novel biologically active methylene derivatives of sydnones. Medicinal Chemistry Research, 2013, 22, 5752-5763.	1.1	11
526	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 5290-5297.	1.4	11
527	Structural modification of diarylpyrimidine derivatives as HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry Research, 2015, 24, 220-225.	1.1	11
528	Tumour-specific cytotoxicity and structureâ€“activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones. Bioorganic and Medicinal Chemistry, 2016, 24, 2206-2214.	1.4	11
529	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains. European Journal of Medicinal Chemistry, 2019, 176, 11-20.	2.6	11
530	Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy. Molecules, 2020, 25, 1050.	1.7	11
531	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C. Bioorganic and Medicinal Chemistry, 2021, 30, 115927.	1.4	11
532	Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorganic Chemistry, 2020, 96, 103595.	2.0	11
533	Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. European Journal of Medicinal Chemistry, 2022, 227, 113903.	2.6	11
534	Increased resistance of trisomic-21 cells to virus replication: Role of interferon. Virology, 1978, 86, 276-280.	1.1	10
535	Assessment of thein vitrobroad-spectrum antiviral activity of some selected antitumor metallocene and metallocenium complexes. Applied Organometallic Chemistry, 1989, 3, 491-497.	1.7	10
536	Synthesis and Biological Properties of ( ) and (-)-(E)-5-(2-bronovinyl)-21 -deoxy-11 a-Carbauridine. Nucleosides, Nucleotides and Nucleic Acids, 1989, 8, 855-858.	0.4	10
537	Synthesis and Biological Evaluation of 4-Carbamoyl-2-Î²-D-Ribofuranosyl-Pyridine. Nucleosides & Nucleotides, 1991, 10, 883-894.	0.5	10
538	Synthesis of 2?-Deoxy-5-(isothiazol-5-yl)uridine and Its Interaction with the HSV-1 Thymidine Kinase. Helvetica Chimica Acta, 1996, 79, 1462-1474.	1.0	10
539	CXC-Chemokine Receptor 4 Is Not a Coreceptor for Human Herpesvirus 7 Entry into CD4+ T Cells. Journal of Virology, 2000, 74, 2011-2016.	1.5	10
540	BICYCLIC FURO PYRIMIDINE NUCLEOSIDES WITH ARYLOXYPHENYL AND HALOPHENYL SUBSTITUTED SIDE CHAINS AS POTENT AND SELECTIVE VARICELLA-ZOSTER VIRUS INHIBITORS. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1063-1066.	0.4	10

#	Article	IF	Citations
541	Synthesis and antiviral properties of aza-analogues of ganciclovir derived from 5,5-bis(hydroxymethyl)pyrrolidin-2-one. Tetrahedron, 2007, 63, 10587-10595.	1.0	10
542	Synthesis, spectroscopic characterization, in vitro cytotoxic and structure activity relationships of some mononuclear Ru(II) complexes. Journal of Coordination Chemistry, 2013, 66, 1031-1045.	0.8	10
543	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2. Bioorganic and Medicinal Chemistry, 2018, 26, 2051-2060.	1.4	10
544	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. European Journal of Medicinal Chemistry, 2020, 206, 112811.	2.6	10
545	Antiviral Classification. , 2021, , 121-130.		10
546	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2021, 64, 13604-13621.	2.9	10
547	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel. European Journal of Medicinal Chemistry, 2021, 226, 113868.	2.6	10
548	Establishment of mutant murine mammary carcinoma FM3A cell strains transformed with the herpes simplex virus type 2 thymidine kinase gene.. Cell Structure and Function, 1986, 11, 295-301.	0.5	10
549	Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy. Antiviral Therapy, 1998, 3, 81-88.	0.6	10
550	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK. Journal of Medicinal Chemistry, 2022, 65, 2122-2138.	2.9	10
551	Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. Journal of Medicinal Chemistry, 2022, 65, 2458-2470.	2.9	10
552	Gliotoxin analogs as inhibitors of reverse transcriptase. 1. Effect of lipophilicity. Journal of Medicinal Chemistry, 1978, 21, 796-799.	2.9	9
553	Syntheses et Activites Biologiques de Nouvelles (E)-Alcenyl-5 Desoxy-2â€² Uridines. Nucleosides & Nucleotides, 1985, 4, 447-462.	0.5	9
554	Targets for the Antiviral Activity of Pyrimidine and Purine Nucleoside Analogues. Nucleosides & Nucleotides, 1987, 6, 197-207.	0.5	9
555	Synthesis and Biological Activity of C-Acyclic Nucleosides of Imidazo [1,5-a]-1,3,5-Triazines. Nucleosides & Nucleotides, 1987, 6, 663-678.	0.5	9
556	Influence of Fluorination of the Sugar Moiety on the Anti-HIV-1 Activity of 2',3'-Dideoxynucleosides. Nucleosides, Nucleotides and Nucleic Acids, 1989, 8, 1121-1122.	0.4	9
557	Synthesis and Antiviral Activities of Some Novel Carbocyclic Nucleosides. Nucleosides & Nucleotides, 1996, 15, 1335-1346.	0.5	9
558	Impact of 9-(2-phosphonylmethoxyethyl)adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cells. FEBS Letters, 1999, 445, 92-97.	1.3	9

#	Article	IF	Citations
559	A guided tour through the antiviral drug field. Future Virology, 2006, 1, 19-35.	0.9	9
560	Eco-Friendly Synthesis and Biological Evaluation of New Quinoline-Based Dialkyl Î±-Aminophosphonates. Letters in Organic Chemistry, 2007, 4, 332-338.	0.2	9
561	Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile 2008 (2nd Edition): RNA Viruses. Antiviral Chemistry and Chemotherapy, 2008, 19, 63-74.	0.3	9
562	Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 513-519.	2.5	9
563	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2020, 185, 111874.	2.6	9
564	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors. European Journal of Medicinal Chemistry, 2021, 225, 113769.	2.6	9
565	Syntheses of 4-[1-(2-deoÃ—y-Î²-<FONT SIZE=-1>D</FONT>-ribofuranosyl)]-derivatives of 2-substituted-5-fluoroaniline: "cytosine replacement" analogs of deoÃ—ycytidine for evaluation as anticancer and antihuman immunodeficiency virus (anti-HIV) agents. Canadian Journal of Chemistry, 2000, 78, 1081-1088.	0.6	9
566	Anti-complement activity of polynucleotides. Biochemical and Biophysical Research Communications, 1975, 67, 255-263.	1.0	8
567	PolyadenylicÂ·polyxanthylicÂ·polyuridylic acid triple helix. Biochemistry, 1977, 16, 1039-1043.	1.2	8
568	Influence of various experimental conditions on the inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on varicella-zoster virus replication in cell culture.. Tohoku Journal of Experimental Medicine, 1984, 143, 441-449.	0.5	8
569	Syntheses, Activites Biologiques et Etude Conformationnelle D'Alcynyl-5 Desoxy-2â€² Uridines. Nucleosides & Nucleotides, 1985, 4, 429-445.	0.5	8
570	Serum and urine concentrations of oral bromovinyldeoxyuridine in humans as monitored by a bioassay system based on varicella-zoster virus focus inhibition. Journal of Medical Virology, 1987, 22, 17-23.	2.5	8
571	Facile preparation of 9-H-pyrimido [4,5-b] [1,4] diazepine derivatives from 4,5-diaminopyrimidines and ethyl pyruvate.. Tetrahedron, 1994, 50, 13511-13522.	1.0	8
572	Novel l-lyxo and 5â€²-deoxy-5â€²-modified TSAO-T analogs: synthesis and anti-HIV-1 activity. Antiviral Research, 1996, 32, 149-164.	1.9	8
573	Synthesis and antiviral evaluation of pyridine fused heterocyclic and nucleosidic derivatives. Tetrahedron, 1997, 53, 8225-8236.	1.0	8
574	Synthesis and Antiviral Activity of 6-Benzoyl-Benzoxazolin-2-One and 6-Benzoyl-Benzothiazolin-2-One Derivatives. Antiviral Chemistry and Chemotherapy, 1999, 10, 87-97.	0.3	8
575	Fomivirsen. Drugs, 1999, 57, 381.	4.9	8
576	BICYCLIC NUCLEOSIDE INHIBITORS OF VARICELLA-ZOSTER VIRUS (VZV): EFFECT OF TERMINAL UNSATURATION IN THE SIDE-CHAIN. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 763-766.	0.4	8

#	Article	IF	Citations
577	SYNTHESIS OF 1-(2-DEOXY-Î²-D-RIBOFURANOSYL)-2,4-DIFLUORO-5-SUBSTITUTED-BENZENES*: â€œTHYMINE REPLACEMENTâ€•ANALOGS OF THYMIDINE FOR EVALUATION AS ANTICANCER AND ANTIVIRAL AGENTS. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 41-58.	0.4	8
578	Synthesis and Biological Activity of a Series of Methylene-Expanded Oxetanocin Nucleoside Analogues. Monatshefte FÃ¼r Chemie, 2002, 133, 499-520.	0.9	8
579	Discovery of a Tat HIV-1 Inhibitor through Computer-Aided Drug Design. Spectroscopy, 2003, 17, 639-645.	0.8	8
580	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: Synthesis, biological investigation and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2013, 21, 6477-6483.	1.4	8
581	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. MedChemComm, 2013, 4, 810.	3.5	8
582	Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors. European Journal of Pharmaceutical Sciences, 2014, 62, 334-341.	1.9	8
583	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. Chemical Biology and Drug Design, 2016, 87, 283-289.	1.5	8
584	Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs. Molecules, 2020, 25, 1581.	1.7	8
585	Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIVâ€‘1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 2022, 53, 116531.	1.4	8
586	Ribavirin for HIV. Lancet, The, 1991, 338, 450-451.	6.3	7
587	Synthesis of penicillamine- and cysteine-containing nucleoamino acids as potential antivirals and aminopeptidase B inhibitors. Journal of the Chemical Society Perkin Transactions 1, 1991, , 43-48.	0.9	7
588	Synthesis and Biological Properties of2-Amino-3-fluoro-2,3-Dideoxy-D-Pentofuranosides of Natural Heterocyclic Bases. Nucleosides & Nucleotides, 1991, 10, 1743-1757.	0.5	7
589	Palladium-catalyzed synthesis of (E)-5-(2-acylvinyl)-2â€²-deoxyuridines and their antiviral and cytotoxic activities. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1627-1632.	1.0	7
590	Synthesis and Anti-HIV Properties of 1,2,4,6-Thiatriazin-3-one 1,1-Dioxtoe Nucleosides. Nucleosides & Nucleotides, 1998, 17, 901-910.	0.5	7
591	Quinolone Nucleosides: 6,7-Dihalo-N-Î²- and Î±-Glycosyl-l 4-dihydro-4-oxo-quinoline-3-carboxylic Acids and Derivatives. Synthesis, Antimicrobial and Antiviral Activity. Nucleosides & Nucleotides, 1998, 17, 2255-2266.	0.5	7
592	Effects of topical and subconjunctival cidofovir (HPMPC) in an animal model. Current Eye Research, 1998, 17, 560-566.	0.7	7
593	Synthesis and Antiviral Activity of Carbocyclic Nucleosides Incorporating a Modified Cyclopentane Ring. Part 3: Adenosine and Uridine Analogues. Nucleosides & Nucleotides, 1999, 18, 2253-2263.	0.5	7
594	Synthesis of aza-analogues of Ganciclovir. Tetrahedron, 2006, 62, 10325-10331.	1.0	7

#	Article	IF	Citations
595	Pre-exposure chemoprophylaxis of HIV infection: Quo vadis?. Biochemical Pharmacology, 2012, 83, 567-573.	2.0	7
596	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-substituted-hydrazinecarbothioamides. Medicinal Chemistry Research, 2013, 22, 2014-2022.	1.1	7
597	Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Chinese Chemical Letters, 2021, 32, 1020-1024.	4.8	7
598	First Example of a 4-Amino-1,2,4,6-thiatriazine 1,1-Dioxide Derivative. Heterocycles, 1996, 43, 2199.	0.4	7
599	FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis?. Viruses, 2022, 14, 770.	1.5	7
600	Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections. Viruses, 2021, 13, 2410.	1.5	7
601	Preparation and biological properties of a highly active poly(G) Â· poly(C) inducer of interferon. Antiviral Research, 1984, 4, 339-350.	1.9	6
602	Current leads in antiviral chemotherapy. Journal of Antimicrobial Chemotherapy, 1986, 17, 399-402.	1.3	6
603	Synthesis of 5-(1-substituted ethyl)uracil derivatives and some of their chemical and biological properties. Journal of the Chemical Society Perkin Transactions 1, 1987, , 457.	0.9	6
604	Dodecanucleotides Containing (E)-5-(2-Bromovinyl)-2â€²-Deoxyuridine: Influence of a Bulky Major Groove Substituent on Duplex Stability and Endodeoxyribonuclease Eco Ri Recognition. Nucleosides & Nucleotides, 1988, 7, 347-363.	0.5	6
605	Synthesis of 3'-Fluoro-3'-Deoxyribonucleosides; Anti-HIV-1 and Cytostatic Properties. Nucleosides, Nucleotides and Nucleic Acids, 1989, 8, 1123-1124.	0.4	6
606	Potent inhibitory effects of the 5'-triphosphates of (E)-5-(2-bromovinyl)-2'-deoxyuridine and (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil on DNA polymerase gamma. FEBS Journal, 1990, 190, 463-467.	0.2	6
607	Synthesis and Biological Study of the Cyclopentenyl Carbocyclic Nucleoside Analogue of 5-Azacytidine. Nucleosides & Nucleotides, 1992, 11, 1123-1135.	0.5	6
608	Evaluation of Antiherpetic Compounds Using a Gastric Cancer Cell Line: Pronounced Activity of BVDU against Herpes Simplex Virus Replication. Microbiology and Immunology, 1996, 40, 359-363.	0.7	6
609	Synthesis and Antiviral Evaluation of N-Î²-D-Ribosides of Ergot Alkaloids. Nucleosides & Nucleotides, 1997, 16, 97-106.	0.5	6
610	Monitoring Drug Resistance for Herpesviruses. , 2000, 24, 151-170.		6
611	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.3	6
612	SYNTHESIS AND IN VITRO EVALUATION OF NOVEL ANTI-VARICELLA-ZOSTER VIRUS (VZV) NUCLEOSIDES. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 653-656.	0.4	6

#	Article	IF	Citations
613	THIOSUGARS. VIII.* PREPARATION OF NEW 4â€²-THIO-L-LYXO PYRIMIDINE NUCLEOSIDE ANALOGUES. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1625-1645.	0.4	6
614	Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors, Part 4[1]. Synthesis and Anti-HIV Activity of N-1-Î²-Carbonyl-6-naphthyl-methyl Analogues of HEPT. Monatshefte FÃ¼r Chemie, 2005, 136, 1233-1245.	0.9	6
615	Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile (2nd Edition): Retroviruses and Hepadnaviruses. Antiviral Chemistry and Chemotherapy, 2008, 19, 75-105.	0.3	6
616	Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru(II) complexes. Journal of Coordination Chemistry, 2010, 63, 4332-4346.	0.8	6
617	Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase. MedChemComm, 2014, 5, 468.	3.5	6
618	Design, Synthesis, and Biological Evaluation of Novel 4â€Aminopiperidinylâ€linked 3,5â€Disubstitutedâ€1,2,6â€thiadiazineâ€1,1â€dione Derivatives as <scp>HIV</scp>â€1 <scp>NNRTI</scp>s. Chemical Biology and Drug Design, 2015, 86, 107-113.	1.3	6
619	Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. European Journal of Medicinal Chemistry, 2021, 214, 113204.	2.6	6
620	Therapy of poxvirus infections. , 2007, , 375-395.		6
621	A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951â€“2021). Medicinal Research Reviews, 2021, , .	5.0	6
622	From design to biological mechanism evaluation of phenylalanine-bearing HIV-1 capsid inhibitors targeting a vital assembly interface. Chinese Chemical Letters, 2023, 34, 107611.	4.8	6
623	Interferon induction by platinum(II)-poly(I)Â·poly(C) complexes. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1983, 741, 358-363.	2.4	5
624	Inhibitory Activity of (E)â€5â€(2â€Bromovinyl)â€2â€²â€Deoxyuridine on the Salmonid Herpesviruses, Oncorhynchus masou Virus (OMV) and Herpesvirus salmonis. Microbiology and Immunology, 1988, 32, 57-65.	0.7	5
625	Antiviral Activity of Heparin and Dextran Sulfate against Human Immunodeficiency Virus (HIV) in Vitro. Annals of the New York Academy of Sciences, 1989, 556, 419-421.	1.8	5
626	Novel Carbocyclic Nucleosides Containing a Cyclopentyl Ring. Adenosine and Uridine Analogues. Archiv Der Pharmazie, 1997, 330, 265-267.	2.1	5
627	In vitroSensitivity of Kaposi's Sarcoma Cells to Various Chemotherapeutic Agents Including Acyclic Nucleoside Phosphonates. Antiviral Chemistry and Chemotherapy, 1999, 10, 129-134.	0.3	5
628	Total syntheses of novel dideoxynucleoside analogues using chiral amino acids. Tetrahedron Letters, 2000, 41, 6191-6194.	0.7	5
629	NOVEL ARYL SUBSTITUTED BICYCLIC FURO NUCLEOSIDES AS EXTREMELY POTENT AND SELECTIVE ANTI-VZV AGENTS. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 287-296.	0.4	5
630	Sodium and potassium benzeneazophosphonate complexes with crown ethers: Solid-state microwave synthesis, characterization and biological activity. Polyhedron, 2009, 28, 3449-3458.	1.0	5

#	Article	IF	Citations
631	Synthesis, spectroscopic characterization and in vitro antitumor activities of some novel mononuclear Ru(II) complexes. Chinese Chemical Letters, 2012, 23, 466-469.	4.8	5
632	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. Bioorganic and Medicinal Chemistry, 2021, 40, 116195.	1.4	5
633	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. Bioorganic Chemistry, 2021, 116, 105353.	2.0	5
634	Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability. European Journal of Medicinal Chemistry, 2022, 240, 114581.	2.6	5
635	Renaturation of Inactivated Interferons by â€œDefensive Reversible Denaturationâ€. Preparative Biochemistry and Biotechnology, 1974, 4, 383-393.	0.4	4
636	Interaction of polyriboinosinic acid. Polyribocytidylic acid with human lymphoblastoid cells. Biochemical and Biophysical Research Communications, 1980, 92, 833-838.	1.0	4
637	Antitumor cell and antimetabolic effects of 5-ethyl-2â€²-deoxyuridine and 5â€²-substituted 5-ethyl-2â€²-deoxyuridine derivatives. Investigational New Drugs, 1984, 2, 35-47.	1.2	4
638	Role of Adenosine Kinase in the Biological (Antiviral and Anticellular) Activities of Adenosine Analogues. Nucleosides & Nucleotides, 1987, 6, 423-424.	0.5	4
639	Mechanism of Antiviral Activity of 5-Ethyl-2â€²-Deoxyuridine. Nucleosides & Nucleotides, 1987, 6, 421-422.	0.5	4
640	Protective activity of lipid A analogue GLA-60 against murine cytomegalovirus infection in mice. Journal of Medical Virology, 1993, 40, 222-227.	2.5	4
641	Synthesis and antiviral evaluation of 3â€²-substituted thymidine analogues derived from 3â€²-amino-3â€²-deoxythymidine. Tetrahedron, 1995, 51, 5369-5380.	1.0	4
642	Novel Tsao Derivatives. Synthesis and Anti-HIV-1 Activity of Allofuranosyl-TSAO-T Analogues. Nucleosides & Nucleotides, 1996, 15, 349-359.	0.5	4
643	Daunorubicin Derivatives Obtained from Daunorubicin and Nucleoside Dialdehydes. Nucleosides & Nucleotides, 1997, 16, 87-95.	0.5	4
644	Pyridazines 92. Synthesis of dialkyldipyridazinodiazepinones as potential HIVâ€1 reverse transcriptase inhibitors. Journal of Heterocyclic Chemistry, 2001, 38, 125-130.	1.4	4
645	Synthesis of Imidazo[1,2-a]pyridine Derivatives as Antiviral Agents. Arzneimittelforschung, 2001, 51, 304-309.	0.5	4
646	Strategies in the Design of Antiviral Drugs. , 2005, , 1135-1190.		4
647	Cytotoxicity and Antiviral Activity of Palladium(II) Quinolylmethylphosphonate Complexes. Synthesis of Acetate Complexes. Letters in Drug Design and Discovery, 2006, 3, 528-533.	0.4	4
648	A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate. Expert Opinion on Pharmacotherapy, 2009, 10, 2935-2937.	0.9	4

#	Article	IF	Citations
649	Strategies for the treatment of dengue virus infections: a narrative account. Future Medicinal Chemistry, 2010, 2, 601-608.	1.1	4
650	Synthesis and cytostatic evaluation of some 2-(5-substituted-2-oxoindolin-3-ylidene)-N-substituted hydrazine carbothioamide. Medicinal Chemistry Research, 2011, 20, 1229-1234.	1.1	4
651	Synthesis and biological evaluation of some stilbene derivatives. Medicinal Chemistry Research, 2011, 20, 1349-1356.	1.1	4
652	An intriguing and facile one-pot catalytic synthesis of N-alkylated lactams. Monatshefte FÃ¼r Chemie, 2013, 144, 515-521.	0.9	4
653	Antimicrobial and cytotoxic activities of turbinariaconoides (j.agardh) kuetz. Iranian Journal of Pharmaceutical Research, 2010, 9, 411-6.	0.3	4
654	Anno 2021: Which antivirals for the coming decade?. Annual Reports in Medicinal Chemistry, 2021, 57, 49-107.	0.5	4
655	Structure-Based Discovery of Novel NH₂-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH₂-Naphthyl-Diarylpyrimidine to NH₂-Biphenyl-Diarylpyrimidine. Journal of Medicinal Chemistry, 2022, 65, 8478-8492.	2.9	4
656	Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors. European Journal of Medicinal Chemistry, 2022, 240, 114563.	2.6	4
657	Synthesis and Biological Evaluation of some Acyclic Nucleoside Cyclic Phosphoramidate Derivatives. Nucleosides & Nucleotides, 1987, 6, 793-802.	0.5	3
658	Therapy for herpesvirus infections. Current Opinion in Infectious Diseases, 1991, 4, 795-803.	1.3	3
659	Therapy for herpesvirus infections. Current Opinion in Infectious Diseases, 1992, 5, 816-826.	1.3	3
660	Synthesis of [1-[2',5'-bis-O-(t-Butyldimethylsilyl)-Î²- L-ribofuranosyl] thymine]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (L-TSAO-T). Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 299-301.	0.4	3
661	The Synthesis and Antiviral Activity of Some New S-Adenosyl-L-homocysteine Derivatives and Their Nucleoside Precursors. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 545-547.	0.4	3
662	Polyanion inhibitors of human immunodeficiency virus. Part IV. - polymerized anionic surfactants: Influence of the density and distribution of anionic groups on the antiviral activity. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 397-402.	1.0	3
663	Stereospecificity of 6'-C-Neplanocin A Analogues as Inhibitors of S-Adenosylhomocysteine Hydrolase Activity and Human Immunodeficiency Virus Replication. Nucleosides, Nucleotides and Nucleic Acids, 1998, 17, 479-486.	0.4	3
664	Syntheses of 1-[(2-Hydroxyethoxy)methyl]- and 1-[(1,3-Dihydroxy-2-Propoxy)methyl]- Derivatives of 5-Substituted-2,4-difluorobenzene: Unnatural Acyclo Thymidine Mimics for Evaluation as Anticancer and Antiviral Agents. Nucleosides, Nucleotides and Nucleic Acids, 2000, 19, 1397-1411.	0.4	3
665	Molecular structures and ab initio molecular orbital calculations of the optically active derivatives of 1-aminocyclopropane-1-carboxylic acid. Journal of Molecular Structure, 2003, 655, 229-241.	1.8	3
666	Antiviral Drug Targets and Strategies for Emerging Viral Diseases and Bioterrorism Threats. , 2005, , 83-113.		3

#	Article	IF	Citations
667	Editorial overview: Antiviral strategies. Current Opinion in Virology, 2016, 18, v-vi.	2.6	3
668	6-Benzylidene-2-[4-(pyridin-3-ylcarboxy)benzylidene]cyclohexanones: A novel cluster of tumour-selective cytotoxins. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1611-1615.	1.0	3
669	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127287.	1.0	3
670	Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity. Bioorganic Chemistry, 2021, 111, 104905.	2.0	3
671	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. Bioorganic and Medicinal Chemistry, 2021, 42, 116239.	1.4	3
672	Herpesvirus infections in immunocompromised patients. Cancer Treatment and Research, 1995, 79, 149-171.	0.2	3
673	BVDU ((E)-5-(2-Bromovinyl)-2â€™-Deoxyuridine). , 1984, , 89-104.		3
674	Molecular Targets for Selective Antiviral Chemotherapy. , 1988, , 97-122.		3
675	Synthesis and Biological Activity of N-(arylsulfonyl) Valine Hydrazones and Assistance of NMR Spectroscopy for Definitive 3D Structure. Letters in Drug Design and Discovery, 2019, 16, 974-983.	0.4	3
676	A â€œclick chemistryâ€•approach to the straightforward synthesis of new 4-aryl-1,2,3-triazolocarbanucleosides. Arkivoc, 2009, 2010, 152-168.	0.3	3
677	Expansion of the Sâ€“CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase. European Journal of Medicinal Chemistry, 2022, 238, 114512.	2.6	3
678	[18] Procedures for the measurement of interferon mRNA distribution in induced mouse cells. Methods in Enzymology, 1981, 79, 125-131.	0.4	2
679	Failure of Athymic-Nude Mice Sensitized with Bacillus Calmette-Guerin to Produce Interferon in Response to Purified Protein Derivative. Experimental Biology and Medicine, 1983, 172, 260-264.	1.1	2
680	Optimal Treatment Regimens for 5â€²-Deoxy-5-fluorouridine, with or without (E)-5-(2-Bromovinyl)-2â€²-deoxyuridine, against Various Tumors in Mice. Japanese Journal of Cancer Research, 1990, 81, 431-435.	1.7	2
681	Stereospecific Synthesis and Anti-HIV Activity of (Z)2'- and (E)3'-Deoxy-2'(3')-C-(chloromethylene) Pyrimidine Nucleosides. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 533-536.	0.4	2
682	Introductory Article: Anti-infectives: Present status of HIV protease inhibitors in the control of HIV infections. Expert Opinion on Investigational Drugs, 1996, 5, 153-154.	1.9	2
683	Synthesis of 1,5-Anhydrohexitol Nucleosides as Mimics of AZT, D4T and DDC. Nucleosides & Nucleotides, 1996, 15, 325-335.	0.5	2
684	Novel Analogues of the Anti-HIV-1 Agent TSAO-T Modified at the 3â€²-Spiro Moiety. Nucleosides & Nucleotides, 1997, 16, 1033-1036.	0.5	2

#	Article	IF	Citations
685	Synthesis and Biological Evaluation of 2â€²,3â€²-Dideoxy-3â€²-Fluororibofuranosyl Purine Nucleosides. Nucleosides & Nucleotides, 1997, 16, 1083-1086.	0.5	2
686	Synthesis of Novel Carbocyclic Nucleosides with a Modified Cyclopentane Ring and Evaluation of Their Antiviral Activity. Nucleosides & Nucleotides, 1999, 18, 641-642.	0.5	2
687	92 Ara-A-5â€²-phenyl methoxy alaninyl phosphate as a prodrug of the adenine arabinoside -monophosphate: synthesis and anti viral evaluation. Antiviral Research, 2000, 46, A63.	1.9	2
688	Synthesis of 1-(2-deoxy-?-D-ribofuranosyl)-2,4- difluoro-5-(2-halo-1-hydroxyethyl)benzenes and related derivatives: ?thymine replacement? analogs of deoxythymidine for evaluation as antiviral and anticancer agents. Drug Development Research, 2001, 52, 492-499.	1.4	2
689	SYNTHESIS ANDIN VITROANTIVIRAL ACTIVITY EVALUATION OF 9-(2-AZIDO-2,3-DIDEOXY-Î²-D-THREO-PENTOFURANOSYL)ADENINE DERIVATIVES. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1053-1057.	0.4	2
690	Therapeutic Approaches to HHV-6 Infection. Perspectives in Medical Virology, 2006, 12, 291-301.	0.1	2
691	Corrigendum to â€œEnantioselective synthesis of homocarbocyclic-2â€²-oxa-3â€²-azanucleosidesâ€. Tetrahedron, 2007, 63, 4190.	1.0	2
692	Mouse and Hamster Models for the Study of Therapy against Flavivirus Infections. Novartis Foundation Symposium, 2008, , 218-232.	1.2	2
693	Nâ€²-[4-[(Substituted imino)methyl]benzylidene]-substituted benzohydrazides: synthesis, antimicrobial, antiviral, and anticancer evaluation, and QSAR studies. Monatshefte FÃ¼r Chemie, 2013, 144, 825-849.	0.9	2
694	Antiviral Drug Development â€“ Success and Failure: A Personal Perspective with a Japanese Connection. Antiviral Chemistry and Chemotherapy, 2013, 23, 45-55.	0.3	2
695	Design, synthesis, and biological evaluation of novel 5â€Alkylâ€6â€Adamantylmethylpyrimidinâ€4(3H)â€ones as <scp>HIV</scp>â€1 nonâ€nucleoside reverseâ€transcriptase inhibitors. Chemical Biology and Drug Design, 2016, 88, 380-385.	1.5	2
696	Designing Novel Hydrazinecarbothioamides as Potential HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Proceedings (mdpi), 2017, 1, 274.	0.2	2
697	1984â€”Discovery of the First Anti-HIV Drug, Suramin. Viruses, 2021, 13, 1646.	1.5	2
698	Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19). Microbiology Australia, 2021, 42, 47.	0.1	2
699	The HIV-1 Reverse Transcription (RT) Process as Target for RT Inhibitors. , 0, .		2
700	Charge modification of plasma and milk proteins results in antiviral active compounds. Journal of Peptide Science, 1999, 5, 563.	0.8	2
701	Structure-Based design of [(2-Hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives as nonnucleoside HIV-1 reverse transcriptase Inhibitors: From HEPTs to Sulfinyl-substituted HEPTs. Bioorganic Chemistry, 2022, 126, 105880.	2.0	2
702	Linker optimization of HEPT derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors: From S=O to CHOR. Chinese Chemical Letters, 2023, 34, 107663.	4.8	2

#	Article	IF	Citations
703	Antiviral agents and immunity. Clinical Immunology Newsletter, 1985, 6, 103-107.	0.1	1
704	Sugar and Base-Modified 2',3'-Dideoxynucleosides as Potential Anti-Aids Drugs. Nucleosides, Nucleotides and Nucleic Acids, 1989, 8, 1125-1126.	0.4	1
705	Synthesis and Evaluation of Antiviral Activity of 3'-C-Cyano-3'-Deoxynucleosides. Nucleosides, Nucleotides and Nucleic Acids, 1989, 8, 837-840.	0.4	1
706	Adducts of Mannose 6-Phosphate with 5-Iodo-2â€²-Deoxyuridine and 2-5A as Potential Antiviral Agents. Nucleosides & Nucleotides, 1989, 8, 1387-1398.	0.5	1
707	Methods in Anti-HCMV Research. , 2000, 33, 129-152.		1
708	An In Situ Pig Liver Esterase Assay as a Useful Predictive Tool for the Likely In Vitro Anti Viral Activity of Phosphoramidate Pro-Drugs. Nucleosides & Nucleotides, 1999, 18, 967-969.	0.5	1
709	Difluorinated carbaacyclonucleosides: Synthesis and evaluation of antiviral activity. Journal of Chemical Research, 2001, 2001, 311-312.	0.6	1
710	New anti-HIV Agents and Targets. ChemInform, 2003, 34, no.	0.1	1
711	Antiviral Research at the Rega Institute (KU Leuven), Now 50 Years Old. Antiviral Chemistry and Chemotherapy, 2004, 15, 223-233.	0.3	1
712	New Approaches Toward anti-HIV Chemotherapy. ChemInform, 2005, 36, no.	0.1	1
713	Stereoselective Synthesis of Novel Aristeromycin Analogues as Potential Antiviral Agents. Synthesis, 2008, 2008, 3253-3260.	1.2	1
714	Synthesis of 5â€²â€Nâ€(Î±â€Aminoâ€Î²â€mercaptoacyl)aminoâ€5â€²â€deoxynucleosides as potential antiviral compounds. Archiv Der Pharmazie, 1991, 324, 497-500.	2.1	1
715	Vesicular stomatitis virus (VSV) as a paradigm for predicting antiviral activity against Ebola virus (EBOV). Marmara Pharmaceutical Journal, 2015, 2, 141-141.	0.5	1
716	Letter to the editor. Life Sciences, 2020, 252, 117714.	2.0	1
717	An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus in Mice. Proceedings (mdpi), 2020, 50, .	0.2	1
718	Microwave Assisted Synthesis, Characterization of Some New Isatin and Thiophene Derivatives as Cytotoxic and Chemopreventive Agents. Letters in Drug Design and Discovery, 2012, 9, 934-941.	0.4	1
719	Inhibition of Oncornavirus Activities by Polynucleotide Analogues. , 1979, , 539-551.		1
720	Epidemiology and Clinical Outcomes of HIV Infection in South-Central China: A Retrospective Study From 2003 to 2018. Frontiers in Public Health, 0, 10, .	1.3	1

#	Article	IF	Citations
721	Additions and Corrections - Resolution of Aristeromycin Enantiomers.. Journal of Medicinal Chemistry, 1985, 28, 1965-1965.	2.9	0
722	Potent and Selective Anti-HIV Activity of 5-Chloro-Substituted Derivatives of 3'-Azido-2',3'-Dideoxycytidine, 3'-Fluoro-2',3'-Dideoxycytidine, and 2',3'-Didehydro-2',3'-Dideoxycytidine. Annals of the New York Academy of Sciences, 1990, 616, 480-482.	1.8	0
723	The Synthesis, Fluorescence and Antiviral Studies of 3â€²-Amino-2â€²,3â€²-Dideoxythymidine/substituted 10-Cyano-9-isothiocyanatoanthracene Adducts. Nucleosides & Nucleotides, 1994, 13, 2013-2019.	0.5	0
724	Fluorinated Carbaacyclonucleosides: Synthesis and Evaluation of Antiviral Activity. Nucleosides & Nucleotides, 1995, 14, 1913-1927.	0.5	0
725	Evidence for the Involvement of the Small Subunit of HIV-1 Reverse Transcriptase (RT) in the TSAO-Resistance. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 599-602.	0.4	0
726	Adefovir dipivoxil. Drugs, 1999, 58, 488-489.	4.9	0
727	Synthesis and Antiviral/Antiproliferative Activity of Some N-Sulfonylbenzimidazoles.. ChemInform, 2003, 34, no.	0.1	0
728	Emtricitabine. Drugs, 2003, 63, 2425-2426.	4.9	0
729	Enfuvirtide. Drugs, 2003, 63, 2767-2768.	4.9	0
730	Interactions of the Dimeric Triad of HIV-1 Aspartyl Protease with Inhibitors. Drug Design and Discovery, 2003, 18, 53-64.	0.3	0
731	Synthesis and Biological Evaluation of Carbocyclic Nucleosides with 2â€²,3â€²-Dihomo-xylo-carbocyclic or Carbocyclic Fused to a Tetrahydrofuran Ring. Synthesis, 2004, 2004, 1991-1995.	1.2	0
732	(E)-5-(2-Bromovinyl)-2?-deoxyuridine (BVDU). ChemInform, 2005, 36, no.	0.1	0
733	Aromatic Polycationic Molecules with Restricted Conformations: An Alternative Approach to Antiherpes Agents. Letters in Drug Design and Discovery, 2005, 2, 424-427.	0.4	0
734	Synthesis and Antiviral Evaluation of (-)-3â€²-Methylcarbovir, (-)-3â€²-Methylabacavir, and Modified Purine Analogues. Synthesis, 2009, 2009, 290-296.	1.2	0
735	Synthesis and Biological Evaluation of 6-Substituted Purinylcarbanucleosides with a Cyclopenta[b]thiophene Pseudosugar. Synthesis, 2009, 2009, 2766-2772.	1.2	0
736	Antiviral chemotherapy in 2009:quo vadis?. Future Virology, 2009, 4, 313-315.	0.9	0
737	Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Antiâ€HIVâ€1 Agents. Chemical Biology and Drug Design, 2015, 86, 333-343.	1.5	0
738	Niacin esters of chalcones with tumor-selective properties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1451-1456.	2.5	0

#	Article	IF	Citations
739	Discovery of Biphenyl-Substituted Diarylpyrimidines as New Non-Nucleoside HIV-1 Reverse Transcripttase Inhibitors. Proceedings (mdpi), 2017, 1, 220.	0.2	0
740	Profiles of Prototype Antiviral Agents Interfering with the Initial Stages of Hiv Infection. , 2003, , .		0
741	Anti-HIV agents to be used in drug combination regimens. , 2004, , 1-23.		0
742	Nucleoside Analogues in the Chemotherapy of Viral Infections. , 1988, , 219-232.		0
743	Interactions of the Dimeric Triad of HIV-1 Aspartyl Protease with Inhibitors. Drug Design and Discovery, 2003, 18, 53-64.	0.3	0
744	Selective inhibitors of the replication of poxviruses. , 0, , 283-307.		0
745	Existing Influenza Antivirals: Their Mechanisms of Action and Potential in the Face of Avian Influenza. , 0, , 1-37.		0